Applications of gold nanoparticles to thiol and nitric oxide chemistry by Durocher, Suzanne
University of Windsor 
Scholarship at UWindsor 
Electronic Theses and Dissertations Theses, Dissertations, and Major Papers 
2009 
Applications of gold nanoparticles to thiol and nitric oxide 
chemistry 
Suzanne Durocher 
University of Windsor 
Follow this and additional works at: https://scholar.uwindsor.ca/etd 
Recommended Citation 
Durocher, Suzanne, "Applications of gold nanoparticles to thiol and nitric oxide chemistry" (2009). 
Electronic Theses and Dissertations. 7974. 
https://scholar.uwindsor.ca/etd/7974 
This online database contains the full-text of PhD dissertations and Masters’ theses of University of Windsor 
students from 1954 forward. These documents are made available for personal study and research purposes only, 
in accordance with the Canadian Copyright Act and the Creative Commons license—CC BY-NC-ND (Attribution, 
Non-Commercial, No Derivative Works). Under this license, works must always be attributed to the copyright holder 
(original author), cannot be used for any commercial purposes, and may not be altered. Any other use would 
require the permission of the copyright holder. Students may inquire about withdrawing their dissertation and/or 
thesis from this database. For additional inquiries, please contact the repository administrator via email 
(scholarship@uwindsor.ca) or by telephone at 519-253-3000ext. 3208. 





Submitted to the Faculty of Graduate Studies 
Through the Department of Chemistry and Biochemistry 
In Partial Fulfillment of the Requirements for 
The Degree of Master of Science at the 
University of Windsor 
Windsor, Ontario, Canada 
2009 
© 2009 Suzanne Durocher 
1*1 Library and Archives Canada 
Published Heritage 
Branch 






Patrimoine de I'edition 
395, rue Wellington 
Ottawa ON K1A 0N4 
Canada 
Your file Votre r&ference 
ISBN: 978-0-494-57640-3 
Our file Notre reference 
ISBN: 978-0-494-57640-3 
NOTICE: AVIS: 
The author has granted a non-
exclusive license allowing Library and 
Archives Canada to reproduce, 
publish, archive, preserve, conserve, 
communicate to the public by 
telecommunication or on the Internet, 
loan, distribute and sell theses 
worldwide, for commercial or non-
commercial purposes, in microform, 
paper, electronic and/or any other 
formats. 
L'auteur a accorde une licence non exclusive 
permettant a la Bibliotheque et Archives 
Canada de reproduire, publier, archiver, 
sauvegarder, conserver, transmettre au public 
par telecommunication ou par Plnternet, preter, 
distribuer et vendre des theses partout dans le 
monde, a des fins commerciales ou autres, sur 
support microforme, papier, electronique et/ou 
autres formats. 
The author retains copyright 
ownership and moral rights in this 
thesis. Neither the thesis nor 
substantial extracts from it may be 
printed or otherwise reproduced 
without the author's permission. 
L'auteur conserve la propriete du droit d'auteur 
et des droits moraux qui protege cette these. Ni 
la these ni des extra its substantiels de celle-ci 
ne doivent etre imprimes ou autrement 
reproduits sans son autorisation. 
In compliance with the Canadian 
Privacy Act some supporting forms 
may have been removed from this 
thesis. 
Conformement a la loi canadienne sur la 
protection de la vie privee, quelques 
formulaires secondaires ont ete enleves de 
cette these. 
While these forms may be included 
in the document page count, their 
removal does not represent any loss 
of content from the thesis. 
Bien que ces formulaires aient inclus dans 




DECLARATION OF CO-AUTHORSHIP/PREVIOUS PUBLICATION 
I. Declaration of Previous Publication 
This thesis includes two original papers that have been previously published in 
peer reviewed journals, as follows: 
Chapter 2 
Chapter 3 
Mikula, I., Durocher, S., Martasek, P., Mutus, B. and Slama-
Schwok, A. Isoform-specific differences in the nitrite reductase 
activity of nitric oxide synthases under hypoxia (2009). Biochem 
J. 418(3):673-82. 
Durocher, S., Rezaee, A., Hamm, C , Rangan, C , Mittler, S. and 
Mutus, B. (2009). Disulfide-linked, gold nanoparticle-based 




I certify that I have obtained a written permission from the copyright owners to 
include the above published materials in my thesis. I certify that the above material 
describes work completed during my registration as graduate student at the University of 
Windsor. 
I declare that, to the best of my knowledge, my thesis does not infringe upon 
anyone's copyright nor violate any proprietary rights and that any ideas, techniques, 
quotations, or any other material from the work of other people included in my thesis, 
published or otherwise, are fully acknowledged in accordance with the standard 
referencing practices. Furthermore, to the extent that I have included copyrighted material 
that surpasses the bounds of fair dealing within the meaning of the Canada Copyright Act, 
I certify that I have obtained a written permission from the copyright owners to include 
such materials in my thesis. 
I declare that this is a true copy of my thesis, including any final revisions, as 
approved by my thesis committee and the Graduate Studies office, and that this thesis has 
not been submitted for a higher degree to any other University or Institution. 
II. Co-Authorship Declaration 
I hereby declare that this thesis incorporates material that is result of joint 
research, as follows. Chapter 2 incorporates joint research undertaken by the author under 
the supervision of Dr. Bulent Mutus, by Ivan Mikula and Dr. Anny Slama-Schwok of 
Ecole Polytechnique in Paris, France, and by Dr. Pavel Martasek of Charles University in 
Prague, Czech Republic. Equal amounts of independent data presented in the publication 
were acquired by the author and Ivan Mikula. The other three co-authors contributed 
through research supervision, manuscript preparation, and funding. The data presented in 
this thesis reflect the author's contributions to the publication. 
in 
Chapter 3 was also the result of joint research. In all cases the experimental 
design, data and data interpretation were performed by the author under the supervision of 
Dr. Bulent Mutus. The collaborators, Dr. Chitra Rangan of the University of Windsor, Dr. 
Caroline Hamm of the Windsor Regional Cancer Centre in Windsor, Ontario, Asad 
Rezaee and Dr. Silvia Mittler of the University of Western Ontario in London, Ontario, 
contributed through funding and through discussion of experimental design and data 
interpretation. 
I am aware of the University of Windsor Senate Policy on Authorship and I certify 
that I have properly acknowledged the contribution of other researchers to my thesis, and 
have obtained written permission from each of the co-authors to include the above 
materials in my thesis. 
I certify that, with the above qualification, this thesis, and the research to which it 
refers, is the product of my own work. 
IV 
ABSTRACT 
The first project studied the three nitric oxide synthases under different oxygen 
tensions. We found that eNOS can reduce NO2" to NO in hypoxia and anoxia, using 
endothelial cells and isolated enzymes. This suggests a new role for eNOS in times of 
restricted oxygen. 
In the next project, gold nanoparticles were joined with a disulfide bond-bearing 
crosslinker to create a blue probe that turned red upon reduction with low molecular 
weight thiols. The rate depended on the size of the molecule. Since small thiols help 
control the redox of proteins their quantification helps identify oxidative stress. 
In the third project, seven proteins isolated by gold nanoparticles were identified; 
these may have bound by their surface thiols. Additionally, gold nanoparticles were used 
to S-denitrosylate GSNO, and a flow device was designed that would automate this 
method. The prototype model is manually operated but shows potential to be developed 
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1.1 Nitric Oxide 
1.1.1 Introduction 
Most people are aware of some effects of nitric oxide (NO) with no prior 
knowledge of the molecule itself. It is a component of air pollution, used to treat heart 
disease in the form of nitroglycerin, and the active ingredient of Viagra. Similarly, one of 
the main physiological roles of NO was known before the molecule itself was identified 
as the causative agent: that is the promotion of smooth muscle relaxation (1). The 
diversity of the effects of NO has resulted in interest from different groups of researchers 
such as athletes, doctors and academic scientists. 
There was interest in the 1980s in a molecule dubbed endothelium-derived 
relaxing factor (EDRF). As more was learned about EDRF and NO, Ignarro (2), Palmer et 
al (3) and others independently discovered that they were the same molecule. This was 
only a few years after NO was found to activate the enzyme guanylate cyclase, which was 
already known to promote smooth muscle relaxation through its product cyclic guanosine 
monophosphate (cGMP) (1). Since then, NO research has held immense interest and 
scientists continue to learn more about its importance, underscored by the wide diversity 
of its roles and physiological effects such as platelet aggregation inhibition (4), 
angiogenesis (5), and immune response (6), among others. 
This brief survey will attempt to impart an understanding of the fundamentals of 
NO. Beginning with synthesis and properties, it will then explain the reactions NO readily 
undergoes, touching on the influence this has in health and disease. Finally, current 
detection methods will be described as they are vital to NO research. 
1.1.2 Biosynthesis 
1.1.2.1 Nitric oxide synthase 
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Nitric oxide synthase (NOS) is the enzyme responsible for the biosynthesis of NO. 
There are 3 isoforms, named for their role or location of first discovery: neuronal NOS 
(nNOS), also known as NOS I, which was first isolated in 1990 (7); inducible NOS 
(iNOS), originally discovered in murine macrophages and known as NOS II (8); and 
endothelial NOS (eNOS), also known as NOS III (9). nNOS is further divided into sub-
types [i, a, p\ or y depending on the specific tissue in which it is expressed. eNOS and 
nNOS are constitutively expressed, producing low levels of NO upon receiving a signal. 
iNOS, however, is not expressed until it is activated (1). It can be activated in many tissue 
types, producing high amounts of NO until no longer needed. 
The 3 isozymes share basic structural similarities. NOS is a homodimer, each 
monomer containing an N-terminal oxygenase domain and a C-terminal reductase domain 
(10). The oxygenase domains bind to heme and tetrahydrobiopterin (BH4), while the 
reductase domains contain an electron transport system comprised of nicotinamide 
adenine dinucleotide phosphate (NADPH), flavin adenine dinucleotide (FAD), and flavin 
mononucleotide (FMN). The calmodulin and zinc cofactors are located at the interface 
between monomers, with two cysteine residues from each monomer coordinated to the 
zinc. While eNOS and nNOS bind calmodulin reversibly, its binding to iNOS is 
irreversible. The NOS active sites are highly conserved (9) as they all catalyze the same 
reaction to produce NO from arginine and oxygen (6). An image of NOS can be found in 
Figure 1.1. 
Aside from these fundamental similarities, the NOS isozymes have important 
differences to accommodate their varied roles in the body. They only share 50-60% 
homology with one another and are somewhat different in size (11). eNOS and nNOS are 
mainly located at the cell membrane while iNOS is expressed internally (12). Their 
3 
regulation also varies and will be discussed later. These and other variations between the 
3 isozymes allow them to maintain their separate roles based on the location of their 
expression. 
1.1.2.2 De novo NO synthesis 
NO is a product of the 5-electron oxidation reaction of arginine to citrulline (6). It 
is a multi-step mechanism involving the electron transport system of the reductase 
domain. Electron flow begins with NADPH, through FAD to FMN, which passes one 
electron at a time to the heme iron in the opposite monomer's oxygenase domain, as 
depicted in Figure 1.1. Once the iron is reduced, it is able to bind a molecule of oxygen 
and begin catalysis (13). The first main step is the formation of one mole of NG-hydroxy-
L-arginine (NOHA) from one mole of arginine, NADPH and O2. Next, one electron (i.e., 
0.5 moles of NADPH consumed) is transferred to heme where one more mole of O2 is 
consumed to convert NOHA to citrulline, releasing NO. The overall stoichiometry of the 
reaction is 2 moles of O2 and 1.5 moles of NADPH consumed per mole of arginine to 
produce one mole of NO and one of citrulline (14). Since the reaction occurs at the 
terminal amine of L-arginine, NG-monomethyl-L-arginine (L-NMMA) is a potent 
competitive inhibitor of NOS (15). 
4 
NO + Citrulline 
FADH"< 
, A , J FMNH2 
FADH, 
FMNH- l^y ^ N A D P H 
• NO + Citrulline O2 + Arginine 
Figure 1.1 Structure of the active NOS 
While maintaining differences in sequence and regulation, all 3 of the NOS 
isozymes follow the common, basic structure depicted above. In the catalytically active 
form, it is a homodimer with each monomer comprised of an oxygenase domain, shown 
in gray, and a reductase domain, depicted in pink. Electron flow is shown on the left-hand 
side, where an electron is transferred from NADPH to FAD, then to FMN, and from there 
to the heme of the opposite monomer. Oxygen can bind to the reduced heme and this 
begins the conversion of arginine to citrulline and NO via the NOHA intermediate. The 
image is from Cayman Chemical (caymanchem.com). 
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1.1.3 Physical properties 
NO's small size and hydrophobic nature are responsible for its opportunities for 
reactivity inside the body (1). It is slightly more soluble in water than O2 and it is 9 times 
more soluble in organic solvents than in water (16). This means it can freely diffuse 
across cell membranes as well as react inside them. Since the cell membrane occupies 
only 3% of a cell's volume, it serves to concentrate existing NO into a smaller area, 
enabling faster reactions (1). 
More powerful, however, is the diffusibility of NO. It has a diffusion constant of 
3300 nmV1 in water (17) and takes 2 ms to diffuse out of a 5-u.m cell; therefore, given a 
half-life of 5-10 s, NO is a very effective signaling molecule capable of reaching several 
hundred thousand cells surrounding that in which it was produced (18). To underscore 
this statement, it has been theoretically shown that since NO diffuses more rapidly than it 
reacts, in reactions occurring within NO-producing cells, the NO is more likely to have 
come from a different cell than itself (19). These two properties of solubility and 
diffusibility are thus responsible for the rapid reaction rates and the paracrine nature of 
NO signaling. 
1.1.4 Different forms 
NO has 11 valence electrons, making it an uncharged, paramagnetic, free radical 
and consequently highly reactive (20). Its reactivity is the reason it has a half-life of only 
a few seconds in the body. The nitrogen-oxygen bond itself is a double bond, N=0. While 
it is capable of forming a dimer, 0=N—N=0, the N—N bond is weak and not 
energetically favourable (21), supporting the hypothesis that dimerization is transient at 
best at room temperature and pressure (1). 
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Although it does not readily dimerize, NO reacts with O2 which can be considered 
a biradical given its two unpaired electrons. »N02, another free radical, can be formed 
from NO and O2 in a multi-step reaction (22). This is a strong oxidant which is able to 
abstract hydrogen atoms, add to unsaturated bonds, or react with anions (23). It is also 
able to react with other radicals, including itself and NO. It dimerizes much more readily 
than NO, producing N204 which is a good NO donor to thiols. However, it is unstable and 
dissociates in water to nitrite (NO2) and nitrate (NO3). In addition, »N02 will react with 
NO to form the NO donor N2O3. In water this will remain in equilibrium with two 
equivalents of N0 2 \ but in a hydrophobic environment it is more stable. This includes not 
only the cell membrane but interior hydrophobic pockets of proteins such as protein 
disulfide isomerase (PDI) (24). NO2" can also be formed more directly through a reaction 
between NO, 02 , and H20 (25). 
Oxygen can gain one electron to become superoxide (O2*). It is negatively 
charged and still a free radical because one electron remains unpaired; therefore, it is very 
highly reactive. One common reaction occurs between O2*" and NO, resulting in 
peroxynitrite (ONOO) (26). In aqueous solution it is in equilibrium with its acid, 
ONOOH, and is a strong oxidizing agent and nucleophile. Its most common reaction 
occurs with CO2 to ultimately yield NO3" and bicarbonate (HCO3) (27). However, it also 
reacts with 02" to produce 02 ,
 #N02 and H20, or with NO to form »N02 and N02" (28). 
It had previously been thought that that NO2" and NO3" are inert end products of 
NO metabolism; however, recent evidence shows that they can exert the same influence 
on physiology as NO (29). For example, ingestion of NO2" relaxes smooth muscle and 
leads to an increase in Hb-Fe-NO, similarly to when NO is synthesized (30). Furthermore, 
studies have shown that NO2" is protective during ischemia. While it is known that N02" 
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can be chemically reduced to NO, the reaction is prohibitively slow except in acidic 
conditions such as the stomach (31). In recent years several mammalian enzymes have 
been identified as being capable of catalyzing this reduction in addition to their main 
functions. These include xanthine oxidase, cytochrome c oxidase, and deoxyhemoglobin 
(30). Interestingly, this nitrite reduction is observed only when there is a lack of oxygen: 
xanthine oxidase is up-regulated in hypoxia, and deoxyhemoglobin by definition has no 
bound O2 molecules. While mammals have no such enzyme, commensal bacteria are able 
to reduce NO3" to NO2", making ingested nitrate protective under hypoxia as well. 
In addition to functional similarities, several NO derivatives described above are 
also potent oxidizing agents and generally highly reactive, especially N2O3 and »N02. It is 
this property that allows NO to affect the cell physiology as it does, through reactions 
with lipids, thiols, and other essential components as discussed in the next section. 
1.1.5 Reactions 
Unsaturated fatty acid side chains are subject to hydrogen abstraction, either by 
enzymes or by radicals, resulting in a lipid free radical denoted as L» (32). Oxygen binds 
to it to yield LOO*; this is known as lipid peroxidation. The formation of one LOO* 
begins a chain of reactions whereby affected fatty acids oxidize their neighbours, and so 
on. This regularly occurs in a controlled manner since LOO* serve as signaling 
molecules, and the peroxidation reactions cease upon low oxygen availability. However, 
in a situation of oxidative stress lipid peroxidation becomes uncontrolled, undergoing 
what is known as propagation reactions. 
NO can either initiate or quench these propagation reactions depending on the 
circumstances in the cell. ONOO" is known to directly induce it by abstracting H atoms 
from lipids including low-density lipoprotein (LDL) (33); N02» also has this ability to a 
8 
lesser extent (32). Therefore, in cells where O2" is available, the chance of lipid 
peroxidation by NO-derived species becomes greater. 
Conversely, since NO is a free radical it is able to react with LOO* to form 
LOONO, thus quenching the propagation (34). This may stay as is or hydrolyze to form 
LOOH and N02 . By eliminating the lipid free radical, NO can terminate the reaction 
from propagating further. This is common in conditions where H2O2, transition metals or 
other sources initiate the propagation reaction rather than NOx. NO can also act as a 
quenching agent in the presence of O2"" as long as it is in excess (32). In addition, NO can 
scavenge O2*" and other reactive oxygen species directly, reducing the chance of ONOO" 
initiating lipid peroxidation (35). 
Low molecular weight thiols (LMWT) such as cysteine, N-acetylcysteine, 
glutathione, and others circulate through the blood where they perform a variety of 
functions. They may be reduced, bearing one or more free SH group, or oxidized, 
connected through disulfide (S—S) bonds (36). LMWT maintain the redox status of 
proteins and other high molecular weight thiols (HMWT) through the interchangeability 
of these two forms. For example, one function of PDI is to reduce disulfide bonds of other 
proteins; in the process, PDI becomes oxidized (37). It must return to its original reduced 
state to be able to perform the same reaction again, and LMWT allow this to occur. When 
there is a state of oxidative stress the LMWT reduce proteins to enable them to continue 
their functions, absorbing the oxidized state (36). Reduced LMWT can be replenished 
through de novo synthesis or via reduction by enzymes such as glutathione reductase. 
NO is known to become bound to thiols which are then called S-nitrosothiols, 
denoted as RSNO (38). These can be LMWT and HMWT alike. This formation has 
several effects; one of them, importantly, is to extend the lifetime of NO. As with lipid 
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peroxidation, the ability of a thiol to become S-nitrosylated depends on its environment, 
specifically the local pH and the presence of oxygen and metals. 
A mechanism was proposed in 1997 wherein NO directly reacts with a free thiol 
to produce an intermediate RSN»-OH, which donates an electron to an acceptor to yield 
RSNO (39). However, given NO's relative inability to react with non-radicals, and the 
fact that only specific RSNOs form in vivo, it is not likely that the reaction occurs 
spontaneously (1,40). Since then, copper (Cu2+) has been shown to act as a catalyst for the 
direct 5-nitrosylation by NO (41). Cu2+ can oxidize NO to NO+, as well as oxidize R-SH 
to thiolate, RS". When it performs one or both of the oxidations, the two species can 
directly bind to form RSNO. 
5-nitrosothiols are mainly formed through the reaction between a thiol and an NO 
donor rather than directly (38). Transnitrosylation occurs when an RSNO donates its NO 
group to another thiol. LMWT in the blood such as glutathione (GSH) act as NO 
reservoirs, and upon a stimulus will donate the NO to proteins; this is an important signal 
transduction mechanism. As mentioned above, N2O3 and N2O4 are excellent NO donors 
as well (42). These will react with thiols directly to form RSNO and N02" or N03" 
respectively. In addition, ONOOH - the acid of peroxynitrite - will react with thiolates 
and release peroxide (HOO) along with RSNO; however, this occurs less readily due to 
competition from CO2 (43). 
Although S-nitrosothiols are important carriers of NO, which extend its lifetime 
and mediate signal transduction, they are susceptible to decomposition. While Cu + can 
oxidize NO to NO+, allowing it to bind to thiolates, Cu+ is effective at reducing RSNO 
back to RSH (44). Other metals and reducing agents effect this decomposition as well, 
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and RSNO is light sensitive. Thus, the occurrence of S-nitrosothiols is highly regulated 
via its formation and decomposition pathways. 
Finally, NO will react with metal centres, with the notable example of reaction 
with iron inside heme groups. The M—NO bond is usually linear but may be bent if NO 
acts as an electron acceptor from the metal (1). There are three main reactions that may 
undergo between NO and a hemoprotein such as hemoglobin (45). In one, NO reacts with 
deoxyhemoglobin (Hb-Fe(II)) to form Hb-Fe(II)-NO. Depending on the environment, this 
may then transfer an NO equivalent to a thiol, serving as an NO donor for S-nitrosothiol 
formation (46). NO may also react with oxyhemoglobin (Hb-Fe(II)-02), reducing the 
heme to Hb-Fe(III) and itself becoming oxidized to NO3 in the process by the released O2 
(45). Thirdly, NO may react with Hb-Fe(III) (methemoglobin), resulting in its oxidation 
while methemoglobin becomes Hb-Fe(III)-OH2. 
Many proteins contain a heme group and therefore regulate, or are regulated by, 
NO. Hemoglobin, myoglobin, cytochrome P450, and xanthine oxidase are a handful of 
examples. Importantly, NO activates guanylate cyclase by binding to its heme group, 
culminating in smooth muscle relaxation (47). Binding leads to a conformational change 
in which the weak bond between Fe(II) and its axial ligand, histidine 105, is broken (48). 
The active site then becomes exposed, substantially improving the affinity for its 
substrate, guanosine triphosphate (GTP). The product, cyclic guanosine monophosphate 
(cGMP), activates cGMP-dependent protein kinases and phosphodiesterases (PDE); 
PDE3 stimulates the sarcoplasmic reticulum calcium pump (SERCA2) to sequester 
calcium, leading to the relaxation of smooth muscle (49). This example highlights the 
significance of NO's ability to bind to metal centres of proteins. 
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Overall, the reactivity of NO can be either positive or detrimental to the cell, 
depending in part on its concentration (50). Under normal circumstances the amount of 
NO is sufficient to reversibly activate certain enzymes, such as guanylate cyclase (47), or 
inhibit others through S-nitrosylation, such as PDI (24). In the event of high 
concentrations of NO, however, nitrosative stress can occur in which excessive levels of 
ONOO", N203 and other highly reactive species are produced. These can react with 
proteins unnecessarily, initiate lipid peroxidation, or damage DNA when unchecked (1). 
Therefore, it is critical that the body strictly regulates its NO supply to ensure that it can 
perform its functions without extraneous and damaging reactions occurring. 
1.1.6 Transport 
As stated above, NO is able to freely diffuse due to its small size and 
hydrophobicity. However, free NO has a short half-life and is more likely to react than to 
diffuse for very long (19). RSNOs therefore act as vehicles for the transport of NO from 
cells into serum, through the circulatory system, and to specific tissues. 
PDI has been shown to S-denitrosylate RSNOs such as GSNO or PDI-SNO (24). 
This can produce free NO or PDI itself may become 5-nitrosylated in the process. In 
addition, N2O3 formed in a hydrophobic region inside PDI may directly S-nitrosylate 
PDI's active site thiols. Since PDI is known to be excreted to the cell surface in low 
amounts, and may cycle back in as well (51), it is likely that PDI carries NO across the 
cell membrane where it is then released by free PDI. This would serve as an important 
mechanism to bring NO from a location of high concentration - inside an NO-producing 
cell or platelet - to a site of low concentration, the cell exterior (24). 
5-nitrosoalbumin (Alb-SNO) is one of the primary reservoirs of NO in human 
blood (52). Although it only has one free thiol able to be 5-nitrosylated, the concentration 
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of Alb-SNO may be as high as 5 uM due to the abundance of albumin circulating (1). 
Studies have shown that hydrophobic pockets in albumin facilitate the formation of N2O3, 
which can then S-nitrosylate the same albumin (53). Additionally, transnitrosylation 
reactions occur readily from low molecular weight RSNOs, especially GSNO and S-
nitrosocysteine (CysNO), to albumin (52). Alb-SNO may thus be a transport vessel to 
circulate NO in the blood while it is released in places where it is needed. Hemoglobin 
binds NO both in its heme and by S-nitrosylation of cys93 of the P subunit, but its role in 
the possible transport of NO remains unclear (54). 
1.1.7 Regulation 
The formation of RSNOs and metal-NO complexes regulates the levels of free 
NO, and facilitates its transport to tissues where its activity is needed. However, most of 
the regulation of the amount of NO or NOx occur at the level of the enzyme NOS. eNOS 
and nNOS are the most similar to one another and consequently are regulated in similar 
manners (1). Before it is catalytically active, e/nNOS must form a dimer and bind all of 
its cofactors; the cofactor which has the most influence on this process is calmodulin (55). 
e/nNOS exists as a monomer before its activation by Ca2+. When NO is required, Ca2+ is 
released to the cytosol where it binds to calmodulin. This induces a conformational 
change in calmodulin, allowing it to bind to specific consensus sites on certain proteins. 
On NOS the site is located such that two calmodulins bind to two oxygenase domains, 
bringing them together (Figure 1.1). Dimerization is further stabilized by the cofactor 
BH4. Holoenzyme assembly is thus the main temporal regulation of the amount of NO 
produced by those two isozymes. 
eNOS and nNOS are also regulated spatially. These isozymes are active when 
they are associated with the cell membrane. eNOS associates with caveolae when it is 
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myristoylated and palmitoylated, and while it is there it is constitutively phosphorylated 
at serine 1179, making it active (56). It is inactive in the cytosol when it lacks 
phosphorylation at that site. nNOS is also active at the plasma membrane where it 
localizes through protein-protein interactions (57). The last major sources of e/nNOS 
regulation are substrate availability, namely arginine and O2 (58), and feedback inhibition 
by NO (59). 
iNOS has its own forms of regulation. Calmodulin binding to iNOS is so tight that 
it is considered a subunit more so than a cofactor, and consequently Ca + availability has 
no effect on induction of NO synthesis (55). Rather, the synthesis and inhibition of iNOS 
itself are the main sources of regulation (1). In most cell types, iNOS is not expressed 
until a stimulus induces it. Effective stimulants include lipopolysaccharide (LPS) (60), 
cytokines such as interleukin 1 or tumour necrosis factor (TNF) (61), and endotoxins. 
Once activated, iNOS synthesizes copious amounts of NO continuously until it is 
stopped. One method of down-regulation is feedback inhibition by NO itself through its 
ability to bind to the heme group, which is the site of catalysis (62). iNOS is also limited 
by arginine availability (58); arginase is co-induced along with iNOS, ensuring that 
arginine will deplete so that NO levels will no longer increase after a certain length of 
time (63). iNOS is eventually degraded by the usual cellular mechanism and once the 
induction signal is no longer present, it will stop being produced by the cell. 
1.1.8 Detection methods 
Several detection methods exist that are specific for one form of NO; others are 
more general and simply detect NOx. 4,5-diaminofluorescein diacetate (DAF-2-DA) is 
commonly used on cells for the purpose of detection (64). The acetate groups allow it to 
enter cells, wherein they are cleaved. NOx inside the cell - »N02, N203, and other reactive 
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forms - reacts with DAF-2 in the presence of oxygen, resulting in the formation of a 
fluorescent product that can be quantified with a microscope. As a probe that only 
requires 30 minutes to finish reacting, this makes it a convenient detector for changes in 
NO concentrations in the cell after a stimulus such as lipopolysaccharide. 
Nitric oxide analyzers (NOA) are available from Sievers (General Electric) and 
can be used to detect either NO or NO2" by chemiluminescence (65). The purge vessel can 
be filled with acetic acid and 50 mg of sodium iodide. The iodide ions reduce injected 
N02" to NO, with the acid providing protons for the reaction, while the injected solution 
is carried to the NOA. Inside, the NO is mixed with ozone, O3, and they react to form an 
excited NO2* which releases a photon to become N02#. The photon is detected in the 
photomultiplier tube and displayed in the software as a peak; the area under the peak is 
directly proportional to the number of photons detected, which in turn is directly 
proportional to the number of NO molecules produced. Therefore, by taking the integral 
of the peak area and interpolating it into an NO2" standard curve, one can calculate the 
concentration of NO2 originally injected. If NO is being measured directly instead of 
N02" then acid and iodide are not needed; simply water or buffer can be used to fill the 
purge vessel so that only NO itself will be detected. This can be used for a variety of 
solutions including cell culture media, exhaled breath, or serum. 
The biotin switch assay is a commonly used method to detect 5-nitrosylated 
proteins, developed in 2001 by Jaffrey et al (66). In the first step, methyl 
methanethiosulfonate (MMTS) is added to a sample of S-nitrosoprotein(s) to block free 
thiols with a methyl group. Once excess MMTS is removed, ascorbate is added to reduce 
the S-NO bond, leaving newly formed free thiols. Finally, biotin is conjugated to the 
protein through a short thiol-reactive crosslinker. Disulfide bonds are not affected by this 
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process. In short, biotin is conjugated to proteins only at sites that were S-nitrosylated, 
making S-nitrosoproteins detectable by Western blot through anti-biotin primary 
antibodies. This method is useful for determining whether a particular protein is able to 
be S-nitrosylated, or for determining the proteome of S-nitrosoproteins in serum, among 
other applications. 
These are the most commonly used methods for their respective applications. 
While they are for the most part effective, they still all have their drawbacks. DAF reacts 
with radicals inside the cell which are not necessarily NOx (67), and the biotin switch 
assay is convoluted and has been known to produce false positives (68). Therefore, as NO 
research continues to develop, so will its detection techniques. 
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1.2 Gold Nanoparticles 
1.2.1 History 
Gold nanoparticles (AuNP), also referred to as colloidal gold, have been used for 
millennia, but it is only in the last -150 years that they have been extensively 
characterized and studied (69). The first known cultures to make use of AuNP were 
ancient Egypt and China (400-500 years B.C.E.) which used the wine-red solution as a 
dye for glass and ceramic due to its brilliant colour; this is still in practice today. In 
addition, solutions of AuNP were thought to be medicinal and were drank to cure a 
variety of ailments throughout the middle ages and up until the 19th century (70). 
In 1857 Michael Faraday published the first scientific investigation into the 
properties of the gold nanoparticles (71). While he was not the first to speculate that the 
particles were too small to view with the naked eye (69), he was able to estimate them to 
be in the 10-nm range. He also realized that he could produce them by reducing the 
AuCU" ion. Since then, a variety of methods have been established to synthesize AuNP 
which will be briefly outlined below. 
1.2.2 Synthesis 
Many types of nonmetal and metal nanoparticles exist, including iron, copper, 
silver, cadmium, and platinum (72); however, for the purpose of brevity, only synthesis 
methods of AuNP will be discussed here. As mentioned above, Faraday was the first 
person to synthesize AuNP by reducing AuCLf with phosphorus in CS2 (71). Currently 
used methods are able to produce nanoparticles of specific sizes and shapes. The 
Turkevich method (73), as modified by Frens (74), uses trisodium citrate to both reduce 
aqueous AuCU" and stabilize the resultant spherical AuNP. While Turkevich's protocol 
produced nanoparticles with a 20-nm diameter, Frens was able to vary the ratio of AuCLf 
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and citrate to result in nanoparticles ranging from 16 to 147 nm. The method has been 
further modified by various groups including Grabar et al (75) to produce smaller 
spherical AuNP - in the case of Grabar's group, 12 nm in diameter. 
The seeded growth method is used to control the shape of the AuNP (76). In this 
protocol, AuCLf is mixed with trisodium citrate and the resultant "seed" is mixed in 
specific proportions with cetyltrimethylammonium bromide (CTAB), HAuCU, and 
ascorbic acid. Simply by adjusting the concentrations of each reagent as well as the 
timing and sequence of each reagent's addition, one can obtain nanoparticles shaped like 
triangles, rods of specific aspect ratios, hexagons, cubes, and others (77). 
Gold nanoparticles can be produced using reducing agents other than trisodium 
citrate. The Brust-Schiffrin method utilizes tetraoctylammonium bromide to transfer 
AuCLf to toluene where it is reduced by NaBHU (78). The nanoparticles are commonly 
protected by the subsequent addition of a monolayer of thiol. Alternatively, top-down 
methods can be used for synthesis in which a larger material is effectively whittled down 
to the nanoparticles; these include photolithography and electron beam lithography (79-
80). 
While this description of AuNP synthesis is not exhaustive, these are some of the 
most commonly used methods which have been refined over the past 1-2 decades. It is 
clear that just by using the methods discussed above, one can obtain nanoparticles of any 
desired size and shape and consequently develop a variety of applications. 
1.2.3 PDMS and synthesis of surface gold nanoparticles 
Poly(dimethylsiloxane) (PDMS) is a type of silicone used in many household and 
industrial products, such as contact lenses and microfluidic devices (81). Its notable 
features are that it conforms to the shape of its container (82), it is transparent, 
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inexpensive (81), and it is chemically inert, though it can be made reactive through 
oxidation if needed. PDMS is prepared by mixing the vinyl-containing, silicon-based 
monomer with a crosslinker that includes silyl (SiH) groups in the presence of a platinum 
catalyst and heat (82). It forms a three-dimensional network based on two reactions. The 
primary reaction occurs between the SiH of the crosslinker and the vinyl group of the 
monomer, shown in Reaction 1: 
—Si-H + CH2=CH-Si— -> — Si-CH2-CH2-Si— (1) 
The secondary reaction is favoured in a high excess of crosslinker. The Si-H group is 
hydrolyzed to become Si-OH and this reacts with either another Si-OH or with Si-H to 
form Si-O-Si chains, as seen in Reactions 2 and 3: 
—Si-H + HO-Si— -> — Si-O-Si— + H2 (2) 
—Si-OH + HO-Si— <-> —Si-O-Si— + H20 (3) 
Changing the ratio of monomer to curing agent changes the polymer's properties: for 
example, adding more crosslinker makes PDMS more rigid. Although it was omitted 
from Reactions 1-3 for simplicity, each silicon atom is bonded to methyl groups or 
hydrogen atoms wherever a bond is not shown, making PDMS very hydrophobic and thus 
inert. 
In 2007, Zhang et al (83) published a new technique which allows AuNP to be 
formed on the surface of PDMS. Simply by incubating a 0.5% (w/v) solution of AuCLf 
on the surface of the pre-formed polymer for 24-48 hours, they were able to obtain a pink 
layer of nanoparticles on the surface. Their explanation is that excess SiH groups acted as 
the reducing agent, and the nanoparticles embedded into the pores between crosslinker 
molecules. Adjusting the r\ - the ratio of curing agent to monomer - resulted in 
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morphology and size variation; for example, a ratio of 0.06 led to the formation of 
spherical nanoparticles with an average diameter of 7 nm, while a ratio of 0.1 resulted in 
variably-shaped nanoparticles averaging 13 nm in diameter. 
The Mutus lab recently optimized this process to achieve a greater density of 
AuNP on the surface of the PDMS (unpublished observations). PDMS was polymerized 
using a ratio of either 0.02 or 0.04 and then AuCLf and trisodium citrate were 
simultaneously added to the surface. With this method the citrate acts as the reducing 
agent and the large pores caused by the low r\ gives the nanoparticles a site to embed. The 
colour of the solution is a darker red compared to when there is a lack of citrate, 
indicating that a higher density of nanoparticles is present on the PDMS surface. 
1.2.4 Localized surface plasmon resonance 
The characteristic brilliant colour of gold nanoparticles is a property unique to 
materials in the 1-100 nm range (84). They behave neither as bulk objects nor as single 
molecules. At this point, their identities becomes negligible and the only factors affecting 
their colour are size, shape, and the dielectric constants of the nanoparticles and the 
surrounding media (85). Gold has d-orbital electrons that travel more freely than those of 
lower orbitals. Since the AuNP are smaller than the wavelength of light, passing light 
waves are able to influence the positions of all the d electrons of a nanoparticle, rather 
than individual atoms. The light causes them to cohesively oscillate between ends of the 
nanoparticles, creating a dipole (84). This is known as localized surface plasmon 
resonance (LSPR). 
The frequency of the oscillation lies in the visible region of the light spectrum and 
absorbs strongly at characteristic wavelengths. In the case of unmodified 11-nm spherical 
AuNP in water, the LSPR absorption peaks at 520 nm. The exact size of the nanoparticles 
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does not greatly affect this peak. However, if the nanoparticles were rod-shaped then the 
resonance is more complicated, as there is one transverse and one longitudinal plasmon 
resonance, each with their own absorbance peak (86). Altering the aspect ratio greatly 
influences the overall oscillation frequency and therefore the colour. Thus, each shape of 
AuNP has its own characteristic LSPR absorption. 
The presence of other molecules on the surface is the factor which has the greatest 
effect on the LSPR absorption for nanoparticles of given size and shape. Sulfur has a 
strong attraction to AuNP. It has been shown with x-ray crystallography that while the 
distance between gold atoms within a nanoparticle is 2.8-3.1 A, the distance between gold 
and sulfur atoms is 2.2-2.6 A (87). The bond is not covalent, but it is far stronger than 
electrostatic, so that thiol-containing molecules are stably attached to the surface. Each 
sulfur atom binds between two gold atoms of the nanoparticle. The presence of bonded 
molecules changes the electron density on the surface of the nanoparticles and 
consequently a small red-shift in absorbance peak is seen (84). Many of the applications 
of AuNP involve coating the surface with molecules via their thiols, so this phenomenon 
is frequently observed. 
When molecules are added to AuNP such that they become linked together into 3-
dimensional networks, the LSPR absorption undergoes a more extensive shift (88). The 
crosslinking molecules act as conductors for the electrons, with interparticle distance 
(determined by crosslinker length) controlling the conductivity (89). Consequently, the 
plasmon resonance becomes synced for all of the connected AuNP, leading to a new 
LSPR absorption. Specifically, the absorbance peak will broaden and red-shift, though the 
extent will depend on the nature and length of the connecting molecules. This colour 
change is commonly exploited in applications of AuNP. 
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1.2.5 Applications of AuNP 
Gold nanoparticles are brightly coloured, are able to undergo colour change when 
crosslinked, and are visible in transmission electron microscopy (TEM). They can be 
synthesized in solution or on a surface, are dense enough to centrifuge, and enhance the 
fluorescence of nearby molecules (70,90). They are similar in size to some proteins and 
are non-cytotoxic (91). These properties make them useful in a large variety of 
applications. Here, only a selection will be discussed with the intention of portraying the 
versatility of AuNP. 
AuNP are becoming important assets in bioimaging. In one example, angiogenesis 
was monitored in rabbits using AuNP specifically targeted to neovasculature (92). They 
were made paramagnetic and bonded to molecules reactive to avP3 integrins. These 
targeted and paramagnetic nanoparticles were injected into rabbits fed high-cholesterol 
diets, and control rabbits on a normal diet. MRI was done using typical hospital protocol. 
The presence of nanoparticles greatly enhanced the visibility of the newly forming 
vasculature and the researchers could detect a 47% increase in angiogenesis in 
cholesterol-fed rabbits over controls. The MRI process took about 2 hours, allowing rapid 
detection of one of the warning signs before a stroke or heart attack; this experimental 
design may also be used to image angiogenesis in tumours. 
Surface-enhanced Raman scattering is an advancement of Raman spectroscopy 
(93). The surface plasmons from nanoparticles become coupled to the molecule of 
interest, which enhances the Raman signal up to 1014 times (94). Once again the shape of 
the nanoparticles plays a role; for example, rod-shaped nanoparticles cause higher signals 
than spherical ones (95). Regardless of the shape, the sensitivity is so highly improved 
that single molecules become detectable. This is not only important for the typical 
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chemistry done, but the heightened sensitivity makes it useful in biological settings, for 
example the detection of specific molecules in low concentrations. Thus, the use of AuNP 
increases the scope of experiments to which Raman scattering can be applied. 
The colour change exhibited by clusters of AuNP has been exploited to various 
ends. The reaction between two complimentary DNA strands, each conjugated to AuNP, 
brings the nanoparticles close enough together to induce the LSPR absorption shift 
described above (96). When reflected light is measured from this reaction, using ~50-nm 
AuNP, the detection limit of this assay is 10 fmol of DNA. While this is sensitive, the 
disadvantage is that many nanoparticles must react before a detectable red-shift in 
absorbance occurs. More recently, another group has developed a similar assay in which 
scattered light was measured instead of reflected light by spotting the reaction on a 
waveguide (97). This modification in the detection method is 4 orders of magnitude more 
sensitive, reaching zeptomole quantities, which means the DNA in question does not need 
to be amplified in PCR before it can be detected. This assay can be useful to a variety of 
scientists, such as academic labs doing cloning, or clinical labs identifying certain 
bacteria for rapid diagnosis. 
While this list is not comprehensive, it is clear that AuNP can be easily adapted 
for many uses because of the unique properties endowed on molecules of 1-100 nm size. 
Physics, chemistry, and biology labs all have their own applications for nanoparticles. In 
addition, AuNP are gaining more importance each year in clinical labs through their 
usefulness in imaging, diagnosis and treatment of infections and cancer. With this 
diversity in applications, it is clear that AuNP research is leading the way for new 
technology and will continue to do so for the foreseeable future. 
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CHAPTER 21 
ISOFORM-SPECIFIC DIFFERENCES IN THE NITRITE REDUCTASE 
ACTIVITY OF NITRIC OXIDE SYNTHASES UNDER HYPOXIA 




Nitrite has been observed to promote the same physiological effects as NO", and 
there is an increasing list of enzymes which catalyze the reduction of N02" to NO to allow 
this to occur (31). In addition to that, eNOS has been shown to be protective in hypoxia 
(ischemia, stroke) while iNOS is cardioprotective and nNOS has no apparent role in 
hypoxia. This led Slama-Schwok and coworkers to examine whether eNOS is able to 
reduce NO2" in the absence of oxygen, and they gained evidence to support this 
hypothesis (98-99). 
The goal of the present study was to characterize the roles of all three NOS 
isozymes in the reduction of NO2" to NO under hypoxia and anoxia. The full-length 
enzymes as well as the oxygenase domains alone (which contain the heme moiety) and 
the reductase domains alone were used in various studies performed by the Mutus lab or 
Slama-Schwok's group. In addition, endothelial cells were exposed to different levels of 
oxygen tension, with or without supplemental nitrite, and the NO released from the cells 
was detected after different lengths of time. It was found that eNOS was the only isozyme 
able to reduce the nitrite, and the reductase domain alone had no effect. Additionally, the 
endothelial cells released more NO under hypoxia compared to basal levels while anoxia 
caused the highest increase. These data provide a new role for eNOS as a source of NO in 
pathological conditions in the body, on top of its main role in a normal state. 
2.2 Materials and Equipment 
2.2.1 Materials 
2 Abbreviations used in this chapter: 7-NI, 3-bromo-7-nitroindazole; BH4, tetrahydrobiopterin; ECM, 
endothelial cell media; eNOS, endothelial nitric oxide synthase; eNOSred, eNOS reductase domain; 
HDMEC, human dermal microvascular endothelial cells; iNOS, inducible nitric oxide synthase; L-NMMA, 
NG-monomethyl-L-arginine; NADPH, nicotinamide adenine dinucleotide phosphate; nNOS, neuronal nitric 
oxide synthase; nNOSred, nNOS reductase domain; NO, nitric oxide; N02", nitrite; N0 3 \ nitrate; NOA, 
nitric oxide analyzer; NOx, nitric oxide and related species. 
25 
3-bromo-7-nitroindazole: Cayman Chemical, Burlington, ON 
Argon Grade 5 300 SZ: Praxair Distribution, Division of Praxair Canada Inc., 
Mississauga, ON 
Calcium chloride (CaCi2-6H20): Sigma-Aldrich Canada, Oakville, ON 
Calmodulin: Sent from Dr. Rajendra Sharma, University of Saskatchewan, Saskatoon, SK 
Endothelial cell medium (ECM): ScienCell, Carlsbad, CA 
Endothelial nitric oxide synthase (eNOS), eNOS reductase domain (eNOSred), neuronal 
NOS (nNOS) and nNOSred: purified by and sent from Dr. Anny Slama-Schwok, Ecole 
Polytechnique, Paris, France 
Human dermal microvascular endothelial cells (HDMEC): ScienCell, Carlsbad, CA 
L-arginine: Sigma-Aldrich Canada, Oakville, ON 
Nicotinamide adenine dinucleotide phosphate (NADPH): Sigma-Aldrich Canada, 
Oakville, ON 
NG-monomethyl-L-arginine (L-NMMA): Sigma-Aldrich Canada, Oakville, ON 
Oxygen 2ppm balance argon, size 30, 0.8M3 certified: Praxair Distribution, Division of 
Praxair Canada Inc., Mississauga, ON 
Oxypurinol: Sent from Dr. Anny Slama-Schwok, Ecole Polytechnique, Paris, France 
Sodium chloride (NaCl): ACP Chemicals, Montreal, PQ 
Sodium iodide (Nal): Sigma-Aldrich Canada, Oakville, ON 
Sodium nitrate: Sigma-Aldrich Canada, Oakville, ON 
Sodium nitrite: Sigma-Aldrich Canada, Oakville, ON 
T-75 tissue culture flasks: Sarstedt Inc., Montreal, PQ 
Tetrahydrobiopterin (BH4): Sent from Dr. Guy Guillemette, University of Waterloo, 
Waterloo, ON 
Tris hydroxyaminomethane and Tris-HCl: Sigma-Aldrich Canada, Oakville, ON 
TrypLE™ trypsin: Invitrogen Canada Inc., Burlington, ON 
2.2.2 Equipment 
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2 ml glass vials with black polypropylene screw top and septa: Supelco, Bellafonta, PA 
27.5G syringe needles: Becton-Dickenson, Franklin Lakes, NJ 
Agilent 8453 UV-VIS Spectrophotometer: Agilent Technologies Canada Inc., 
Mississauga, ON 
Bright-Line Hemacytometer: Hausser Scientific, Horsham, PA, USA 
Hamilton® syringe, 1800 series gastight, model 1801RN: Sigma-Aldrich Canada, 
Oakville, ON 
Jouan CR3i Centrifuge: Jouan Inc., Winchester, VA 
Nikon TMS microscope: Nikon, Japan 
NuAire Biological Safety Cabinet Class II Type A/B3: Thermo Electron Corp. Canada, 
Burlington, ON 
NuAire Direct Heat AutoFlow CO2 Automatic Air-Jacketed Incubator: Thermo Electron 
Corp. Canada, Burlington, ON 
Sievers 280i Nitric Oxide Analyzer: General Electric Canada, Mississauga, ON 
2.3 Methods 
2.3.1 Cell culture 
HDMEC were grown in ECM containing basal medium, 5% fetal bovine serum, 
1% endothelial cell growth supplement, and 1% penicillin/streptomycin solution. Cells 
were maintained in T-75 culture flasks at 37°C in 5% CO2 and grown to 80% confluence. 
2.3.2 Treatment of cells 
Once at confluence, the cells' media were decanted and kept aside. Cells were 
trypsinized and concentrated by centrifugation at 1700 rpm for 5 minutes. They were then 
resuspended in either old media or fresh ECM with added 10 \iM NO2" and each 
suspension was aliquotted into septa-topped screw cap glass vials, 0.5 ml per vial. The 
vials were incubated in a 37 °C water bath for the duration of the experiment. In total there 
were 36 vials of cells used in each experiment. One-third had their caps loosely screwed 
27 
on to permit oxygen entry (normoxia). One-third had their caps tightly screwed and were 
blown with argon, via syringe needles inserted through the septa, for 10 minutes followed 
by incubation for 0, 4, 8, 12, 16, or 20 minutes (anoxia). Finally, one-third had their caps 
tightly screwed and were blown with 2 ppm oxygen in argon for 10 minutes and then 
incubated for 0, 6, 12, 16 or 20 minutes (hypoxia). 
2.3.3 Inhibitor treatment of cells 
In another experiment, 80% confluent cells were trypsinized, centrifuged and 
resuspended in fresh media supplemented with 10 îM nitrite. The cells were subdivided 
into suspensions treated with either L-NMMA (500 \iM), 7-NI (10 u.M), oxypurinol (100 
\iM) or left untreated as a control group. These suspensions were distributed into glass 
vials as described above and incubated in anoxia for 0 or 15 minutes after argon 
treatment. An additional group of vials contained media and 10 \iM nitrite but no cells; 
these were also exposed to anoxia for 0 or 15 minutes after argon exposure. 
2.3.4 Nitric oxide detection 
Following the specified lengths of incubation under normoxia, hypoxia or anoxia, 
10 ul of media were injected via a Hamilton gas-tight syringe into a Sievers nitric oxide 
analyzer containing acetic acid and sodium iodide. The average of two repeat injections 
was taken and compared to a nitrite standard curve in order to determine the amount of 
NO detected. 
2.3.5 Nitric oxide detection from in vitro NOS isoforms 
Samples of eNOS, eNOSred, nNOS, and nNOSred were suspended in 50 mM Tris 
buffer with 150 mM NaCl (pH 7.5). These were quantified in the UV-VIS 
spectrophotometer using the extinction coefficients 100 000 M'cm"1 at 396 nm for eNOS 
and nNOS, and 23 300 M^cm"1 at 455 nm for eNOSred and nNOSred. All concentrations 
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were adjusted to 10 \xM using the same buffer. These were aliquotted into the glass vials 
described above. Final concentrations of 10 ^M nitrite, 10 \xM calmodulin (quantified by 
the UV-VIS spectrophotometer with the extinction coefficient 3006 M'cm"1 at 257 nm), 
ImM calcium, 40 uM BH4, and 1 mM arginine were added such that each vial had a final 
volume of 500 (xl. Upon addition of 100 \xM NADPH the vial caps were screwed on 
tightly and blown with argon for 10 minutes; these were incubated for 0 or 15 minutes 
thereafter. Following incubation, 1 ml of the air above the samples was injected into the 
NOA in duplicate. NO production was calculated from a nitrite standard curve. Control 
vials had no NADPH added; in addition, other samples for each isozyme contained 10 
[xM nitrate instead of nitrite. 
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2.4 Results 
2.4.1 NO release by endothelial cells under normoxia, hypoxia or anoxia 
In vitro experiments performed by Dr. Slama-Schwok and colleagues showed that 
eNOS is able to reduce nitrite to NO when oxygen is unavailable for its de novo synthesis 
from arginine. nNOS has a more limited capacity for this and iNOS is unable to do so. To 
further confirm these observations by using a cell system, we chose endothelial cells 
which express eNOS as its NO-producing enzyme (1). 80% confluent cells were 
trypsinized, concentrated and resuspended in media. Half of the cells were replaced into 
the old media decanted before trypsin application, and half of the cells were replaced into 
new media which had 10 \iM nitrite supplementation. Each group was subjected to 
treatment with argon (anoxia), 2ppm O2 in argon (hypoxia) or room air (normoxia) for 
various lengths of time. As shown in Figure 2.1, when there was no nitrite added to the 
cells, there was no measurable change in NOx detected by the NOA over the 20-minute 
time course for any of the three conditions. There was also no significant change 
exhibited by the cells exposed to normoxia in the presence of nitrite. However, an 11% 
increase in NOx levels was detected under hypoxia and a 22% increase was observed 
from the cells exposed to anoxia, confirming that a component of the cells was reducing 
nitrite to NO in the absence of oxygen. Error bars on the data points were the calculated 
standard deviations from two repeat injections of media into the NOA. 
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Figure 2.1 Detection of NO release from nitrite under normoxia, hypoxia and 
anoxia 
Endothelial cells were trypsinized, concentrated and resuspended in either the media in 
which they were grown or in fresh media supplemented with 10 uM nitrite. These were 
subjected to treatment with argon (anoxia), 2ppm O2 in argon (hypoxia) or incubated in 
room air (normoxia) for various lengths of time. Results show that cells placed in the old 
media displayed no change in NOx production over time regardless of oxygen levels. 
When exposed to 10 [xM nitrite, in normal oxygen conditions (gray triangles) there was 
little change in NOx detected. However, after incubation in 2ppm O2 in argon (white 
squares), levels of NOx increased by 11%. Anoxic cells (black diamonds) released the 
most NOx with a 22% increase over normoxia. 
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2.4.2 Effect of inhibitors on NO release by endothelial cells under anoxia 
Since the endothelial cells contain several enzymes which may be responsible for 
the reduction of nitrite to NO under anoxia, we treated cells with different inhibitors to 
determine the correct enzyme based on their effects. L-NMMA is a non-specific NOS 
inhibitor; 7-NI targets the specific isozyme nNOS and to a lesser extent iNOS; and 
oxypurinol inhibits xanthine oxidase. Glass vials were prepared as described above, with 
fresh media and 10 \iM nitrite. There were five categories: no cells, cells that were not 
treated with any inhibitor, and cells treated with one of the three inhibitors listed. After 
10-minute argon exposure, 10 ul of media was injected into the NOA in duplicate either 
immediately or following 15 additional minutes of anoxia. Results after the 15 minutes 
are shown in Figure 2.2 as a percentage of time 0, which was set to 100% for each group 
of vials. There was no change in NOx detected by the NOA in the absence of cells. 
Untreated cells had a similar NOx increase as that seen in Figure 2.1. Oxypurinol had no 
effect on the cells' nitrite reduction; as an inhibitor specific to xanthine oxidase, it shows 
that this enzyme is not involved in the process. The non-specific NOS inhibitor L-NMMA 
nearly eliminated the increase in NOx while the nNOS- and iNOS-specific 7-NI reduced 
it. This verifies the identification of NOS as the responsible enzyme for nitrite reduction 
but does not conclusively point to eNOS alone. Data are represented as the average of two 
repeat injections and their calculated standard deviations. 
32 
125 •] 
° 1 2 0 -
| 1 1 5 -
1 " 0 " 
m 105 • 
re 
"g 100-
V 9 5 -
•O 9 0 -
X 


















Figure 2.2 Effect of inhibitors on nitrite reduction under anoxia 
Endothelial cells were trypsinized and distributed into glass vials as described above. 
Media was supplemented with 10 fxM nitrite and either L-NMMA, 7-NI, oxypurinol or no 
treatment. In addition, vials containing cell-free media and nitrite were included. These 
were exposed to anoxia and incubated for 0 or 15 minutes and media was injected into the 
NOA. As shown in the figure, in the absence of cells (white), there was no difference in 
NOx detected before or after anoxia treatment. Oxypurinol-treated cells (black) exhibited 
the same trend as untreated cells (light gray) indicating a lack of involvement by xanthine 
oxidase. Nitrite reduction was somewhat inhibited by 7-NI (dark gray) and almost 
completely inhibited by L-NMMA (gray hatched) which shows that NOS is the 
responsible enzyme. 
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2.4.3 NO formed by in vitro NOS or NOS reductase domain under anoxia 
As stated in 2.4.1 above, Dr. Slama-Schwok's group showed that eNOS is 
efficient at reducing nitrite to NO, and that nNOS has a limited ability. We then sought to 
determine whether the entire enzyme or simply the reductase domain was necessary to 
perform this reduction. Vials were prepared which contained 10 uM eNOS, eNOSred, 
nNOS or nNOSred; 10 \iM nitrite or nitrate; and all of the required cofactors except 
NADPH. Half of the vials did not have NADPH added at all as a negative control; these 
were blown in argon and then incubated for 15 minutes. The other half had NADPH 
added immediately before the argon treatment. These were then incubated for 15 minutes 
as well. After the incubation period, 1 ml of air above the solution was injected into the 
NOA. There were no detectable peaks generated from either eNOSred or nNOSred, and 
therefore they did not produce NO under anoxia in the presence of all cofactors. Wild-
type nNOS and eNOS released a low basal level of 0.76 and 0.48 pmol of NO, 
respectively, in the absence of NADPH (Figure 2.3). However, in the presence of all 
cofactors including NADPH, NO levels were 1.0 ± 0.08 pmol for nNOS, a ~ 1.3-fold 
increase, and 3.6 ± 0.59 pmol for eNOS which corresponds to a ~7.5-fold increase. NO 
was not detected in any condition in which nitrate was present rather than nitrite. Data is 
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Figure 2.3 Detection of NO released by nNOS and eNOS under argon 
Vials were made containing nitrite, calmodulin, calcium, BH4, arginine and either nNOS 
or eNOS in 50 mM Tris buffer. These were blown with argon either immediately or after 
the addition of 100 uM NADPH and the released NO was detected in duplicate using the 
NOA. nNOS in the presence of NADPH exhibited a ~ 1.3-fold increase in NO production 
compared to its control, while eNOS in the presence of NADPH showed a ~7.5-fold 
increase (*P<0.05). No NO was released in the presence of nitrate. 
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2.5 Discussion 
Dr. Slama-Schwok's group had shown in two prior publications that eNOS is able 
to reduce nitrite to NO in the absence of oxygen, using both purified enzymes and 
endothelial cells (98-99). Here, they further characterized this ability for each isozyme as 
well as studied the oxygenase domain alone. They found that eNOS was the only isoform 
that efficiently released NO, while nNOS only released trace amounts (31). In addition 
they showed that while the oxygenase domain alone released 1.5 uM NO in the presence 
of cofactors and high NO2, this was not as high as the wild-type enzyme at 2.2 uM. They 
had previously studied the role of arginine in the reduction and determined that it was 
necessary for the reaction but not a substrate of NOS in the absence of oxygen. The 
dependence on both arginine and the full enzyme with cofactors show that the structure of 
the enzyme is critical for maximum release of NO from NO2", and infer that structural 
differences between the isozymes are the reason that only eNOS is capable of performing 
this reduction. 
With these data, we sought to confirm the role of eNOS using endothelial cells. 
First, we performed experiments to test the release of NO in the absence of oxygen using 
cells in three conditions: normoxia, hypoxia, or anoxia. Cells were also further divided 
into treatment with 10 uM nitrite or no nitrite added. Figure 2.1 shows that nitrite was 
required for an increase in NO release, and furthermore that the complete lack of oxygen 
resulted in the highest change. The 10-minute incubation in argon was sufficient to drive 
out oxygen, and the septa were sealed with tape afterwards. In addition, each vial of cells 
was only used once, with a different vial in place for each time point. These precautions 
were done to ensure that there would be no holes in the septa to allow the entry of 
oxygen, ruling out de novo synthesis as an explanation for the increase in nitrite. 
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Therefore, this experiment enabled the conclusion that nitrite was being utilized by 
endothelial cells to release NO in the absence of oxygen. Since 10 ^M nitrite is a 
physiologically relevant level, these results are significant to the body in conditions such 
as ischemia (30). 
The next step was to verify that eNOS was responsible for the reduction by the 
cells, rather than xanthine oxidase, cytochrome c oxidase, or another NOS isoform. Sets 
of cells were treated with inhibitors to this end. If the NO release could be attenuated by 
an eNOS-specific inhibitor, but not by the others, then it points to eNOS as the reducing 
enzyme. The inhibitors used were L-NMMA, which is a non-specific inhibitor of all three 
NOS; 3-bromo-7-nitroindazole, which is potent against nNOS and less potent against 
iNOS; and oxypurinol, specific against xanthine oxidase. As seen in Figure 2.2, NOS was 
clearly the responsible enzyme since almost all NOx release was attenuated by L-NMMA, 
and 7-NI was a strong inhibitor as well. If eNOS were the sole isozyme performing the 
reduction, then 7-NI should not have had any effect. However, the IC50 for nNOS, iNOS 
and eNOS are 0.17, 0.29, and 0.86 \iM, respectively (100). This means that while it is the 
most powerful against nNOS, it is not ineffective against eNOS. More in-depth studies 
are thus needed to conclusively state that eNOS is the one isozyme that can reduce nitrite 
to NO in HDMEC. 
The data presented in Figures 2.1 and 2.2 are the results of single experiments. 
While each experiment was done multiple times, the exact amounts of NOx detected 
varied each time. Therefore, the graphs represent the typical results obtained and show 
the trend, namely that in the presence of nitrite, hypoxia resulted in increased NOx 
detected and anoxia led to the highest increase. The control in the inhibitor experiment 
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further verifies that the amount of NO released is substantially higher (15-22% increase) 
than original levels 15 minutes after argon treatment. 
The final experiment that we contributed to this publication was a comparison 
between wild-type and reductase domains of eNOS and nNOS for NO release in the same 
circumstances as the endothelial cells. eNOS, eNOSred, nNOS or nNOSred were placed 
into vials containing calcium, calmodulin, arginine, BH4 and 10 \iM nitrite. As described 
in the previous papers by Slama-Schwok et al, it is necessary to add arginine because it 
induces a conformational change in eNOS necessary for it to carry out the reduction (98). 
Control vials had no NADPH added, and test vials had 100 jxM NADPH added 
immediately before the 10-minute argon treatment and subsequent 15-minute incubation. 
In addition, 10 \iM NO3" was added to half the vials rather than NO2" to determine 
whether NOS can reduce it to NO as xanthine oxidase does. 
There was no signal from any of the vials containing nitrate which indicates 
clearly that NOS is not able to reduce it despite other heme-containing enzymes' ability to 
do so. Those vials can also be considered negative controls for nitrite. The complete lack 
of NO detected from vials without 10 uM NO2" confirms that nitrite is the sole substrate 
for NO generation under anoxia. 
Figure 2.3 shows the results of wild-type nNOS and eNOS. When no NADPH is 
added there is a basal amount of NO released by both isozymes. This may correspond to 
one turnover of the reaction, which cannot be repeated unless NADPH reduces the Fe(III) 
that forms during the nitrite reduction (31). Consequently, the addition of NADPH results 
in a very small increase in NO released by nNOS, and a statistically significant 7.5-fold 
increase by eNOS. This supports the data by Slama-Schwok's group that eNOS is the 
only isozyme that can efficiently reduce the nitrite. In addition, neither reductase domain 
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was able to catalyze the reaction alone; there was no signal in the NOA when they were 
treated with nitrite or nitrate. Given that the reductase domain alone cannot reduce nitrite, 
and the oxygenase domain alone has only a limited ability to do so, the hypothesis that 
the overall structure of eNOS is critical to the reduction of nitrite to NO has been 
supported by these experiments. 
One key difference between the experiments with the cells and the purified 
enzymes was the method of NO detection. When simply eNOS or nNOS were used, the 
headspace above the solution was injected into the NOA, which contained the same Tris 
buffer as the solution. Therefore, only NO itself was being measured in that experiment 
since it is a gas. On the other hand, in both experiments using the endothelial cells, 10 u.1 
of media were injected into the NOA filled with acetic acid and iodide. This means that 
both nitrite and NO were able to be detected. During the minutes of treatment with argon 
or 2 ppm O2 some of the nitrite added to the media would have had time to enter the cells. 
The peaks displayed by the NOA at time 0 in all cases represent the nitrite that was not 
internalized. During the later time points of hypoxia and especially anoxia some of the 
internalized nitrite was likely reduced to NO, which then diffused back out of the cells. 
Therefore, in these cases, the NOA had detected non-internalized nitrite plus NO that 
diffused out of the cells but did not yet go into the gas phase in the headspace. This would 
explain the increase in NOx over time in hypoxia/anoxia as well as the fact that only 
picomole amounts of NO were detected. Although this method of measuring NO is less 
direct than injecting headspace into the NOA, it nevertheless supports the other data that 
eNOS can reduce nitrite to NO in the absence of oxygen. 
In summary, we have shown along with our collaborators, using purified enzymes 
as well as endothelial cells, that wild-type eNOS is the only NOS isozyme capable of 
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reducing nitrite to NO in anoxia. The reductase domain alone does not achieve this, and 
the oxygenase domain only does so in a limited capacity, with the whole enzyme and all 
its cofactors required for maximal reduction. Taken with the necessity for non-substrate 
arginine it can be inferred that the three-dimensional structure of eNOS allows it to be the 
specific isoform involved in hypoxic response. It is logical because oxygen is transported 
by hemoglobin in the blood stream and since endothelial cells line the blood vessels they 
would be among the first cells to detect a decrease in oxygen. Therefore, they would be 
appropriate agents to elicit an emergency response via the effects of NO, such as 
increasing blood flow, in conditions of acute hypoxia such as ischemia. The data support 
this hypothesis although further examination is needed. 
Hypoxia is a dangerous phenomenon that many people experience at some point 
in their lives. This may be from a stroke, atherosclerosis or other form of ischemia, or 
even a sharp change to a high altitude. Consequently, ongoing research is necessary to 
understand the body's responses so that doctors can ameliorate the process in more severe 
cases. The identification of eNOS as an enzyme involved in response thus may have 
important implications in medicine. 
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CHAPTER 33 
DISULFIDE-LINKED, GOLD NANOPARTICLE-BASED REAGENT FOR 
DETECTING SMALL MOLECULAR WEIGHT THIOLS 
3 Reproduced with permission from Durocher et al. (2009). J Am Chem Soc. 131(7):2475-7. ©2009 
American Chemical Society. 
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3.1 Introduction 
As described in Chapter 1, LMWT4 circulate in the blood and regulate the redox 
of proteins - the ratio of reduced to oxidized thiols (36). LMWT are also critical 
reservoirs for NO by 5-nitrosylation (38). By carrying an NO equivalent the RSNO 
extends its lifetime and is able to transport it to where it is needed, transferring it to 
proteins by transnitrosylation (52). For example, RSNOs ameliorate NO-based platelet 
aggregation inhibition but when the NO is transferred to albumin and the thiols are free, 
platelet aggregation occurs more readily (101). In addition, the LMWT have other 
important functions when the thiols are free, including the promotion of T cell 
proliferation via regulation of interleukin-2 (36). 
Both the concentrations and the redox status of thiols (LMWT and HMWT) are 
crucial for the maintenance of homeostasis in the blood. However, there is a distinct lack 
of fast, high-throughput methods to quantify these. Current methods of LMWT 
quantification require the use of high-performance liquid chromatography or capillary 
electrophoresis, followed by photometric or fluorescent detection (102-106). While this 
protocol has high sensitivity, it is a time-consuming, multi-step process. Here, we have 
developed a new reagent that specifically reacts only with free thiols of LMWT -310 Da 
or smaller. The reagent is prepared in minutes and the reaction with thiols can be 
complete within a few minutes. The rate of the reaction depends on the size as well as the 
concentration of thiol. This makes it the most rapid detection system to date with ideal 
4 Abbreviations used in this chapter: P-ME, P-mercaptoethanol; AuNP, gold nanoparticles; BSA, bovine 
serum albumin; DMSO, dimethyl sulfoxide; DSP, dithiobis(succinimidyl propionate); DTNB, 5,5'-
dithiobis(2-nitrobenzoic acid); DTT, dithiothreitol; GSH, reduced glutathione; GSSG, oxidized glutathione; 
HAuCl4, gold (III) chloride; HMWT, high molecular weight thiols; LMWT, low molecular weight thiols; 
NaSH, sodium hydrosulfide; PDI, protein disulfide isomerise; RSNO, S-nitrosothiols. 
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specificity. In addition, the synthesis of a similar reagent to detect LMWT + HMWT was 
attempted. 
3.2 Materials and Equipment 
3.2.1 Materials 
5,5'-dithiobis(2-nitrobenzoic acid) (DTNB): Sigma-Aldrich Canada, Oakville, ON 
P-mercaptoethanol: Fluka/Sigma-Aldrich Canada, Oakville, ON 
Bovine serum albumin, lyophilized powder (BSA): Sigma-Aldrich Canada, Oakville, ON 
Cysteinyl-tyrosine: Genscript Corp., Piscataway, NJ 
Dimethyl sulfoxide (DMSO): ACP Chemicals, Montreal, PQ 
Dithiobis(succinimidyl propionate) (DSP): Fisher Canada, Nepean, ON 
Dithiothreitol (DTT): MP Biomedicals, Solon, OH 
GGGC, GGGGC, GGGGGC and GGGGGGC peptides: Genscript Corp., Piscataway, NJ 
Glutathione, oxidized, lyophilized powder (GSSG): Sigma-Aldrich Canada, Oakville, ON 
Glutathione, reduced, lyophilized powder (GSH): Sigma-Aldrich Canada, Oakville, ON 
Gold (III) chloride (HAuCU): Sigma-Aldrich Canada, Oakville, ON 
Insulin a-chain, recombinant human: Sigma-Aldrich Canada, Oakville, ON 
L-cysteine: Fluka/Sigma-Aldrich Canada, Oakville, ON 
Potassium phosphate monobasic: ACP Chemicals, Montreal, PQ 
Potassium phosphate dibasic: ACP Chemicals, Montreal, PQ 
Sodium hydrosulfide (NaSH): Sigma-Aldrich Canada, Oakville, ON 
Trisodium citrate: Sigma-Aldrich Canada, Oakville, ON 
3.2.2 Equipment 
Acrylic square cuvettes: Sarstedt, Montreal, PQ 
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Agilent 8453 UV-VIS Spectrophotometer: Agilent Technologies Canada Inc., 
Mississauga, ON 
Hettich EBA12 desktop centrifuge: Fisher Scientific, Mississauga, ON 
Freeze dry system/Freezone® 4.5 lyophilizer: Labconco, Kansas City, MO and Maxima® 
C Plus vacuum pump: Fisher Scientific, Mississauga, ON 
Millipore Milli-Q synthesis Q-Gard 2 purification pack: Millipore, Etobicoke, ON 
Philips CM-10 Transmission electron microscope TEM: Electron Microscope Sciences, 
Hatfield, PA 
3.3 Methods 
3.3.1 Synthesis of gold nanoparticles 
Gold nanoparticles (AuNP) were synthesized based on the method of Grabar et al 
(75). 500 ml of a 1 mM solution of HAuCl4 in Milli-Q water was heated and vigorously 
stirred in a round-bottom flask under reflux for one hour. Upon boiling, 50 ml of a 38.8 
mM solution of trisodium citrate was rapidly added. Stirring continued for 10 minutes, 
after which the apparatus was disassembled. The resultant red solution of gold 
nanoparticles were stored at 4°C in the dark. The success of the reaction was verified 
using the UV-VIS spectrophotometer, standard mode, where a peak absorbance at 520 nm 
indicates that -11 nm AuNP are present. 
3.3.2 Synthesis of the gold nanoparticle-based reagent 
3.3.2.1 Coating with DSP 
2.0 mg of DSP was dissolved in 500 |il of DMSO and then 9.5 ml of 95% ethanol 
was added, resulting in a 500 \iM solution. This was added to gold nanoparticles such that 
the entire surface was coated with a monolayer of DSP. A titration was performed to 
ascertain saturation with no free DSP in solution. DSP was added to a cuvette containing 
10 mM phosphate buffer, pH 9.4, in amounts ranging from 0.5 to 2 nmol (0.25 nmol 
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increments) with a final volume of 500 \i\. The spontaneous hydrolysis of the maleimide 
functional group was monitored for one minute at 260 nm using the UV-VIS 
spectrophotometer in kinetics mode. Hydrolysis rates were calculated as the change in 
absorbance at 260 nm per minute. The experiment was repeated in the presence of 50 fil 
AuNP in 450 \i\ of the same buffer. AuNP-bound DSP is protected from spontaneous 
hydrolysis; the saturation point was determined to be the last point before an increase in 
the rate of hydrolysis caused by free DSP, i.e. 1.25 nmol. 
3.3.2.2 Crosslinking with GSSG 
GSSG was dissolved in 10 mM phosphate buffer, pH 7.0, to make a 100 mM 
solution. It was added to AuNP and DSP in 10 mM phosphate buffer, pH 9.4, to a final 
concentration of 7 mM. The reaction was monitored with the UV-VIS spectrophotometer 
in kinetics mode, at 520 nm and 610 nm. The reaction was complete when A610 ceased 
to increase. At this point the now blue solution was centrifuged at 14 000 rpm for 15 
minutes. The supernatant containing excess GSSG in pH 9.4 buffer was removed and the 
pellet was resuspended in 10 mM phosphate pH 7.0, as the final Au-DSP-GSSG reagent. 
3.3.3 Transmission Electron Microscopy 
Samples of AuNP alone and Au-DSP-GSSG reagent were brought to the 
University of Western Ontario. For each sample, 20 îl were placed onto a formvar-
coated, carbon-reinforced 400 mesh grid and allowed to air-dry. The slides were viewed 
in a Philips CM-10 transmission electron microscope (TEM) and pictures were taken with 
an AMT digital camera. 
3.3.4 Purification of recombinant human PDI 
PDI was previously cloned into a pET-28a vector containing the coding for an N-
terminal histidine tag. This vector was expressed in the E. coli strain BL21 (DE3) and the 
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protein harvested according to the published protocol (24). The expressed PDI was 
reduced through incubation with 10 mM DTT for 30 minutes and purified from DTT by 
passing it through a G-25 column. Quantification was performed in the UV-VIS 
spectrophotometer using the extinction coefficient 47 000 M^cm"1 at 280 nm. PDI was 
stored at -80°C until used. 
3.3.5 Reduction of the reagent with small thiols 
The reduction of Au-DSP-GSSG with small thiols was monitored in the kinetics 
mode of the UV-VIS spectrophotometer. Measurements of the wavelengths 520 and 610 
nm were taken every 15 seconds until the reaction was complete, or a maximum of 10 
minutes. The reagent was diluted in the same pH 7.0 buffer to a total volume of 500 îl in 
the cuvette. After starting the kinetics run, a small thiol was added to the solution with a 
final concentration of 1 \iM. The following thiols were used: p-ME, DTT, NaSH, L-
cysteine, GSH, insulin a-chain, and PDI. In addition, trials were run in which no thiol was 
added, to obtain a baseline rate of decomposition. NaSH was used to reduce Au-DSP-
GSSG at a variety of concentrations ranging from 0.125 to 1.5 nmol to determine the 
reagent's detection limit. 
3.3.6 Synthesis of disulfide-linked AuNP with a larger spacer ligand 
3.3.6.1 Oxidation of peptides 
Four peptides were purchased from GenScript: GGGC, GGGGC, GGGGGC, and 
GGGGGGC. They were designed to be like GSSG, but greater in length to leave a larger 
space between AuNP. First, they had to be oxidized to have a disulfide bond meant to be 
cleavable by thiols; this was only done immediately before use. When one of the peptides 
was to be used, it was dissolved in 10 mM phosphate buffer, pH 9.4, to a concentration of 
1 mg/ml. This solution was placed in a small round-bottom flask with a magnetic stir bar 
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and vigorously stirred until the reaction was complete. 5,5'-dithiobis(2-nitrobenzoic acid) 
(DTNB) was used to monitor the reaction. The UV-VIS spectrophotometer was blanked 
with 450 [xl of the phosphate buffer and 50 u.1 of 10 mM DTNB. Then 5 [xl of the peptide 
solution was mixed in the cuvette for 15 seconds and the absorbance at 412 nm was 
taken. This was done for the initial solution and every so often until the absorbance was 0, 
a total lack of free thiol, indicating that the peptide was fully oxidized. At this point the 
solution was lyophilized to concentrate the sample. 
3.3.6.2 Synthesis of the reagent 
The synthesis reaction was performed in a similar manner as for the GSSG 
reagent. 50 u.1 of AuNP was mixed with 3 [iM DSP in 10 mM phosphate buffer, pH 9.4, 
followed 15 s later by 4 mM peptide which had been resuspended in water. The reaction 
was monitored in the UV-VIS spectrophotometer at wavelengths of 520 and 610 nm. 
Following completion of the reaction, the solution was centrifuged once at 14000 rpm for 
10 minutes. 
3.3.6.3 Reduction of the larger reagent 
The goal of synthesizing the larger reagent was to make it cleavable by PDI; 
however, before PDI was used we decided to test with the more inexpensive DTT. 
Therefore, reduction of the newly synthesized reagent was first attempted with 100 uM 
DTT. If reduction was successful then lower concentrations of DTT would be used, 
followed by the same low concentration of PDI. Unfortunately, reduction never occurred. 
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3.4 Results 
3.4.1 Gold nanoparticle synthesis 
Gold nanoparticles were successfully synthesized by the Grabar method. Figure 
3.1 shows UV-VIS spectrophotometer visualization of the localized surface plasmon 
resonance of the AuNP diluted 1/10 in water (A). In addition it shows TEM visualization 
which enables confirmation that the size is 11 ± 1 nm for most nanoparticles (B). 
3.4.2 Au-DSP-GSSG synthesis 
3.4.2.1 Optimization of DSP concentration 
The first step in synthesizing the reagent was to optimize the concentration of 
DSP. It was chosen because it has a disulfide bond, allowing it to bond stably to the 
AuNP, as well as a homobifunctional amine-reactive succinimide group. The succinimide 
hydrolyzes readily in basic pH but is stabilized when bound to AuNP. Its absorbance at 
260 nm in phosphate buffer pH 9.4 was observed over time in the UV/VIS 
spectrophotometer, kinetics mode, with or without AuNP present in the solution. The 
increase in absorbance at 260 nm over the course of one minute determined the rate of 
hydrolysis over various concentrations from 0.5 to 2 nmol. As seen in Figure 3.2, DSP 
has saturated the surface of 50 ul AuNP at 1.25 nmol, corresponding to a final 
concentration of 2.5 ^M. This is based on the rapid increase in hydrolysis rate above that 
amount which indicates that there is now free DSP in solution. This DSP concentration 
was used throughout the rest of the experiments. Data presented in Figure 3.2 are the 
averages of three independent trials and their calculated standard deviations. 
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Figure 3.1 Visualization of newly synthesized AuNP 
Gold nanoparticles were synthesized according to the method of Grabar et al. with 
modifications as described in the Methods. 1 mM HAuCU was heated and stirred under 
reflux until boiling after which 38.8 mM trisodium citrate was added. The citrate reduced 
the gold to Au° and stabilized the spherical shape of the AuNP. The localized surface 
plasmon resonance peaked at 520 nm, making the solution appear red (A). In addition, the 
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Figure 3.2 DSP concentration optimization based on hydrolysis rates 
Various amounts of DSP from 0.5 to 2 nmol were added to cuvettes containing 10 raM 
phosphate buffer, pH 9.4, with (black squares) or without (white diamonds) 50 u,l AuNP. 
The final volume in the cuvettes was 500 ^1 in all cases. The rate of DSP hydrolysis was 
measured as the change in absorbance at 260 nm per minute in the UV/VIS 
spectrophotometer kinetics mode. Saturation of 50 \i\ of AuNP was determined to have 
occurred at 1.25 nmol, or 2.5 \iM, as the last point before an increase in hydrolysis rate. 
This amount of DSP was added to AuNP in all syntheses thereafter. 
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3.4.2.2 Final product formation 
Once the DSP was optimized, a crosslinker was needed to connect the 
nanoparticles. GSSG was chosen because it has one free amine on either side of a 
disulfide bond, making it reactive with the DSP functional group and cleavable by thiols. 
Scheme 1 depicts the strategy utilized to synthesize the reagent. The optimization process 
for GSSG resulted in a final concentration of 7 mM being used. When this amount was 
added to AuNP alone there was no colour change, but when it was added to AuNP coated 
with DSP the solution turned from red to blue, or more specifically the LSPR broadened 
and its maximum shifted from 520 nm to 610 nm (Figure 3.3A). Figure 3.3B shows that 
the reaction between DSP's maleimide and GSSG's free amines was complete after 75 
seconds. Afterwards the solution was centrifuged for 14 000 rpm for 15 minutes in a 
benchtop centrifuge and resuspended in 10 mM phosphate buffer, pH 7.0. At this lower 
pH the reagent was still susceptible to cleavage by thiols but stable at room temperature 
overnight as seen by the constant A610/A520 ratio of hourly spectra taken in the UV/VIS 
spectrophotometer (Figure 3.4). 
3.4.3 TEM of Au-DSP-GSSG 
A sample of the synthesized Au-DSP-GSSG was brought to the University of 
Western Ontario. After drying 20 îl of the solution on the mesh grid as per the 
description in Methods, it was viewed in the TEM. Figure 3.3C shows that the reagent is 
a cluster of many AuNP crosslinked to one another. This is in comparison to the 
monodisperse AuNP seen in Figure 3.IB. The close proximity of many nanoparticles is 
responsible for the change in LSPR absorption yielding the blue colour seen and the 







Scheme 1 Synthesis process of Au-DSP-GSSG 
The strategy for forming the reagent to detect low molecular weight thiols was to first 
coat AuNP with a saturating amount of DSP. It binds to the AuNP via its disulfide bond, 
leaving the amine-reacting maleimide group exposed. Then GSSG was added: its two 
amines react with DSP on different AuNP, bridging them close together to form the 
clusters. The disulfide bond in the middle of the crosslinker enables the breakdown of 
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Figure 3.3 Synthesis of Au-DSP-GSSG 
2.5 \iM DSP and 7 mM GSSG were added sequentially to 50 ul AuNP in 450 [xl of 10 
mM phosphate buffer, pH 9.4. The reaction was monitored in the UV-VIS 
spectrophotometer in kinetics mode. In addition, the final product was brought to the 
University of Western Ontario where it was viewed in the TEM. Figure 3.3A represents 
the course of the reaction from wavelengths 400 to 800 nm. It shows that the original 
AuNP solution had a maximum absorbance at 520 nm, as in Figure 3.1, but as the 
reaction took place the LSPR broadened and red-shifted to a new maximum absorbance 
of 610 nm which visually appears blue. B follows the course of the absorbance at 610 nm 
over time. It shows that the reaction is complete after 75 seconds. Following the reaction, 
the sample was centrifuged and resuspended in a 10 mM phosphate buffer, pH 7.0. One 
TEM image of the Au-DSP-GSSG is depicted in C, showing that it is composed of large 
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Figure 3.4 Overnight stability of Au-DSP-GSSG after synthesis 
Au-DSP-GSSG was synthesized as described above. To test its stability, the reagent was 
monitored overnight in the UV/VIS spectrophotometer in kinetics mode, with readings at 
610 and 520 nm taken every hour. The ratio of A610/A520 was calculated for each time 
point (white diamonds) in two independent trials after synthesis. Data presented are the 
average result and error bars represent the calculated standard deviation for each average. 
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3.4.4 Reaction with thiols 
Au-DSP-GSSG was synthesized so that it could be used as a reagent to detect low 
molecular weight thiols. Consequently, after the synthesis method was optimized, it was 
tested with a variety of molecules containing free thiols. After centrifugation and 
resuspension in 100 u.1 of 10 mM phosphate buffer, pH 7.0, 20 u.1 was taken and diluted to 
500 ul in the same buffer inside a cuvette. It was placed into the UV/VIS 
spectrophotometer, kinetics mode, set to scan every 15 seconds. After the first scan, a 
thiol-containing molecule was mixed into the solution to a final concentration of 1 uM. 
The reaction was allowed to progress to completion, or a maximum of 10 minutes. The 
thiols used were P-ME, DTT, NaSH, L-cysteine, GSH, insulin a-chain, and reduced PDI. 
Only 500 nM of DTT was added because it has 2 free thiols, resulting in a concentration 
of 1 u.M thiol added. The results in Figure 3.5 represent two of all the 1 u.M thiol 
reactions: DTT (A) and GSH (B). These spectra are effectively the reverse of that of 
Figure 3.3A above. C is a photo of the same reaction carried out in a 96-well plate. 
Together these images show that in the beginning the nanoparticles are clustered and 
blue, with the absorbance maximum at 610 nm. As the thiol reduces the GSSG 
crosslinker, the nanoparticles become monodisperse once again and the LSPR shifts back 
to a maximum of 520 nm, resulting in a red solution like that of the original AuNP. The 
other notable result observed in Figure 3.5A and B is that the rate of the reaction is 
affected by the size of the thiol used: DTT was much faster at completing the reduction 
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Figure 3.5 Reduction of Au-DSP-GSSG by 1 uM thiol 
After the synthesis of Au-DSP-GSSG described above, it was diluted in pH 7.0 phosphate 
buffer to a final volume of 500 ul in a cuvette and placed in the UV-VIS 
spectrophotometer in kinetics mode. The sample was scanned every 15 seconds. After the 
first scan, 1 [iM thiol was mixed and the reduction was allowed to progress for 10 
minutes or until completion. These representative spectra show that the reductions are 
essentially the reverse of the synthesis, with the LSPR blue-shifting and becoming more 
narrow as the reaction progresses. It is also seen that larger reducing agents result in 
slower reductions. A shows the reaction with 500 nM DTT, which has two thiols resulting 
in a concentration of 1 uM thiol. With its molecular weight of 154.2 Da, it reduces Au-
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DSP-GSSG at a much faster rate than GSH (B) which has a molecular weight of 307.3 
Da. C is the visual representation of the reaction done in a 96-well plate. There is a clear 
change from blue back to the original red colour, characteristic of 11 nm AuNP, upon the 
addition of 1 \iM thiol. 
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3.4.5 Effects of size and concentration on reduction rates 
The results above show that thiols are able to reduce the blue clusters of Au-DSP-
GSSG back to red nanoparticles coated with DSP-GSH. We used a variety of thiols all at 
the same concentration of 1 \iM to determine the effect that size has on the reaction rate. 
As shown in Figure 3.6A, each small molecule had its own rate as seen by the decrease in 
absorbance at 610 nm over time in the UV/VIS spectrophotometer. It can be seen that 
GSH is the slowest at reducing Au-DSP-GSSG and any thiol-containing molecule larger 
than that, i.e. insulin a-chain and PDI, is unable to react at all. The blank, which was done 
simply by monitoring the reagent in the same conditions but with no thiol added, showed 
a basal rate of reduction caused by the bright light of the spectrophotometer. Interestingly, 
insulin a-chain and PDI exhibited rates slower than that of the blank, which indicates that 
the additional coating of large molecules around the Au-DSP-GSSG clusters has a 
protective effect against the photo-reduction. Figure 3.6B is a graph of the log of each 
initial reduction rate (the change in absorbance at 610 nm per minute, taken from the first 
30 seconds of the reaction) plotted against the log of the corresponding molecules' MW. 
Aside from the outlier DTT, which has a fast rate for its size, there is a clear correlation 
where larger molecules become increasingly slower reducing agents. An asymptote forms 
toward the larger molecules such that at MW larger than that of GSH, approximately 310 
Da, there ceases to be a substantial change in the reaction rate. 
Aside from the effect of size on the small molecules' reduction rates, there is also 
a dependence on concentration. Different concentrations of NaSH, ranging from 0.125 
nmol to 1.5 nmol, were added to Au-DSP-GSSG in the same conditions described above. 
After 10 minutes, which is more than sufficient time for the reaction to complete, the 
difference in absorbance at 610 nm was calculated for each concentration of NaSH and 
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plotted in Figure 3.7. There is a direct correlation seen between the amount added and the 
extent to which it can reduce Au-DSP-GSSG, with an R2 value of 0.983. In a solution 
with a final volume of 500 fxl, this translates to a detection limit below 250 nM. Data are 
the average of three independent trials for each concentration, and the error bars represent 
the calculated standard deviation for each average. 
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Figure 3.6 Effect of size on reduction rate 
1 \iM NaSH, P-ME, DTT, cysteine, GSH, insulin a-chain, or PDI was added to a solution 
of Au-DSP-GSSG diluted to 500 jxl in 10 mM phosphate buffer, pH 7.0 and scanned in 
the UV/VIS spectrophotometer every 15 seconds. A blank was done with no thiol present 
as well. Figure 3.6A exhibits the progress of the reaction as a decrease in absorbance at 
610 nm for each thiol. The results show that each thiol has a characteristic reduction rate, 
which is connected to its molecular weight. B depicts a plot of the log of the initial 
reaction rate, calculated from the change in absorbance at 610 nm per minute, versus the 
log of the molecular weight. It reveals that beyond -310 Da, or the size of GSH, any 
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Figure 3.7 Effect of concentration on reduction 
The concentration of the thiol added plays a role in the reduction of Au-DSP-GSSG. 
Amounts of NaSH ranging from 0.125 to 1.5 nmol were added to a 500 ul solution in 
which the absorbance maximum was 0.2 at 610 nm. After adding the NaSH and allowing 
10 minutes for the reduction to complete, the difference in absorbance at 610 nm was 
calculated for the reaction. Three trials for each concentration were done and the averages 
plotted. It can be seen that the amount of NaSH added is in direct proportion to the extent 
of reduction over a consistent time period. The equation of the line is y = 0.245x + 0.0063 
with R2 = 0.983. The data show that the detection limit of this amount of Au-DSP-GSSG 
is less than 0.125 nmol, corresponding to 250 nM thiol. Error bars represent the standard 
deviation for each averaged sample. 
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3.4.6 Synthesis of disulfide-linked AuNP with a larger spacer ligand 
1 mg/ml of peptide was stirred vigorously in a high pH buffer to achieve thiol 
oxidation, and the reaction was monitored with DTNB until it was complete. Figure 3.8 is 
a representative graph of any time a peptide was oxidized, in this case 5 mg of GGGGC. 
It can be seen that at the given pH of 9.4 and concentration of 1 mg/ml, the reaction took 
approximately 28 hours to complete. The rate, however, depended on the concentration of 
the solution, as more dilute samples oxidize faster. As it progressed the reaction rate 
decreased slightly but overall was nearly linear and thus only time-dependent. 
Once the oxidation was complete, the solution was lyophilized and resuspended in 
water. In a cuvette with 450 \i\ of 10 mM phosphate buffer, pH 9.4, 50 \il of AuNP were 
mixed with 3 u.M DSP, and then various concentrations of peptide. GGGC-CGGG and 
GGGGC-CGGGG were able to form blue products at 4 mM levels while the two larger 
peptides did not turn the solution blue at all, indicating that they did not react with DSP to 
crosslink the AuNP. Figure 3.9 shows a representative synthesis reaction using 4 mM 
GGGGC-CGGGG with the typical AuNP and DSP levels. While Au-DSP-G4CCG4 
appears similar to the synthesis using GSSG, shown in Figure 3.3, this product was 
unable to be reduced by 100 [iM DTT under any condition attempted: pH 9.4, pH 7.4, 
centrifuged to remove excess peptide, or uncentrifuged. Therefore, either the reagent did 
not form the way it was expected, or it did and its particular shape was simply 
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Figure 3.8 Oxidation of GGGGC 
GGGC was dissolved to a concentration of 1 mg/ml in 10 mM potassium phosphate, pH 
9.4. It was stirred in a round-bottom flask with free thiol content monitored using DTNB. 
Free thiols react with DTNB to form a mixed disulfide and TNB" which absorbs at 412 
nm; therefore, absorbance at 412 nm is directly proportional to free thiol added to the 
solution. Results show that this typical oxidation took about 28 hours to complete, based 
on the time required for the absorbance at 412 nm to reach 0. When the reaction was 
complete the solution was lyophilized and kept frozen until use. 
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Wavelength (nm) 
Figure 3.9 Synthesis of Au-DSP-G4CCG4 
50 ^1 of AuNP, 3 fxM DSP and 4 mM G4CCG4 were mixed in 450 ul of phosphate buffer, 
pH 9.4, similarly to the synthesis process of the original reagent using GSSG. While the 
figure resembles Figure 3.3A above, based on the broadening and red-shift of the LSPR 
absorption spectrum, this reagent was unable to be reduced by 100 \iM DTT. 
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3.5 Discussion 
The synthesis of probes has been an interest in the Mutus lab for several years. 
Raturi et al created, and subsequently improved, a sensitive fluorescent probe for 
monitoring PDI reductase activity (107-108). Other group members attempted to 
synthesize a fluorescent probe that reacts specifically with vicinal thiols; this would be 
used to characterize the redox status of PDI and other proteins that have cysteines in close 
proximity with one another. Gold nanoparticles are an ideal basis for a probe due to their 
optical properties. As described in the General Introduction, 11 nm AuNP are red when 
they are free in solution, but a change in LSPR frequency induced by connecting many 
nanoparticles close together results in a change in colour to blue (87-88). 
With this in mind, we set out to exploit the colour change and design a probe that 
binds to two AuNP at once and contains a disulfide bond in the middle. This would cause 
the AuNP solution to turn blue on its synthesis but revert back to red upon reduction of 
the disulfide bond by a free thiol. The initial target planned for the probe was PDI. The 
fluorescent probe that had been already created used GSSG as the linker between two 
eosin molecules, which fluoresce when separated in space from one another. Here, the 
intention was to replace eosin molecules with AuNP and link GSSG to them, producing a 
visible-light probe that performs the same function as the fluorescent one. An AuNP-
based reagent for monitoring PDI reductase activity did not come to fruition, but what did 
result is interesting nonetheless. 
Gold as well as gold nanoparticles are known to form covalent-like bonds with 
thiols (87). Therefore, DSP was chosen as the linker between AuNP and GSSG. Its 
disulfide bond is able to bind to the AuNP, leaving two amine-reactive succinimidyl 
groups exposed. Two DSP molecules on separate AuNP could react with the two free 
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amines of GSSG, resulting in the AuNP being drawn close together and exhibiting the 
LSPR absorption shift that makes them appear blue. 
This reaction does not simply form AuNP dimers. The entire surface area of the 
AuNP is available for reaction with thiols or disulfide bonds; therefore, it was important 
to ensure that DSP saturated the surface, so that no space was left available for GSSG to 
bind to the AuNP directly via its disulfide bond. In addition, having an excess of DSP in 
solution was undesirable since it would compete with AuNP-bound DSP for GSSG. This 
was accomplished as seen in Figure 3.2. We observed that AuNP protected the 
spontaneous hydrolysis of the functional groups of DSP, resulting in little to no increase 
in hydrolysis in the lower concentrations used (0.5-1.25 nmol), as monitored at 260 nm in 
the spectrophotometer. Once the surface was saturated, additional DSP was free in 
solution and consequently not protected from spontaneous hydrolysis. This was seen 
above 1.25 nmol; therefore, that was the amount of DSP used per 50 [xl AuNP. It is 
important to note that increasing the amount of AuNP requires a concomitant increase in 
DSP required to saturate the surface. 
Following that experiment, increasing amounts of GSSG were added to the 
solution until a blue product formed. The 7 mM final concentration of GSSG was a large 
excess over the requirement to saturate the DSP functional groups. It is probable that the 
same protection the AuNP afforded DSP to attenuate spontaneous hydrolysis also made it 
relatively inaccessible to the GSSG, so that a high concentration was required for GSSG 
to "find" the functional groups and react with them. The excess GSSG was simply 
removed by centrifugation and washing of the disulfide-linked product. 
Once the reagent was synthesized it was found that it could not react with thiols 
larger than GSH; in other words, -310 Da was the detection limit of the reagent. Figure 
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3.6A shows the change in absorbance at 610 nm - the maximum absorbance of the blue 
reagent - over time after the addition of each thiol. The first observation made was that 
the smaller thiols led to faster decreases in absorbance at 610 nm, meaning they had 
higher reaction rates. This led to further investigation into the effect of size on reaction 
rate, depicted in Figure 3.6B. With the exception of DTT, the plot of log(reaction rate) vs 
log(MW) made a curve in which higher MW thiols had slower reaction rates until it 
reached an asymptote beginning at GSH. This indicates that any increase in size has 
negligible effect on the probe beyond ~310 Da. 
DTT was the exception to the trend in that it was able to reduce the probe much 
faster than expected for its size. The fact that it has two thiols was taken into account in 
the experiment: whereas the other LMWT were added to the reagent at 1 \iM, only 500 
nM DTT was used. The difference in rate between them may be mechanism-based. In a 
typical reduction reaction (108): 
2RSH + R'SSR' -> RSSR + 2R'SH (4) 
two thiols are consumed per reduction reaction. For DTT the two thiols involved are 
intramolecular, i.e. on the same molecule, and thus execute this reaction more efficiently. 
For the others, the concentration of 1 [xM may be too low for effective numbers of 
intermolecular collisions between the two thiols in comparison with DTT. 
The -310 Da detection limit of the reagent is due to the size and closeness of the 
AuNP. Since many molecules of DSP bind to each nanoparticle, the result of crosslinking 
them is a 3-dimensional network composed of many AuNP, as seen in the TEM 
micrograph in Figure 3.3C. Given that each AuNP is 11 ± 1 nm in diameter, and the 
crosslinking DSP-GSSG is less than that, the complex would be too bulky for a large 
molecule to traverse to the interior and reduce the disulfide bonds. In addition, the 
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dihedral angle of the disulfide bond may play a role in the reagent's ability to be reduced. 
If the Au-DSP-GSSG is oriented such that the disulfide bond is less accessible to outside 
molecules, then smaller ones would be more likely to access the bond and reduce it. 
Although the reagent was designed with the intention of use on PDI, the finding 
that it quantifies solely LMWT was welcome. There are several applications that this 
reagent can have in academic and/or industrial settings. LMWT are important molecules 
in the plasma of blood, both for their redox control of proteins and as reservoirs for NO in 
the form of 5-nitrosothiols (37-38). Since glutathione is known to be at least 90% reduced 
in a healthy individual (109), the reagent may thus be used as a tool to rapidly diagnose 
oxidative stress in plasma samples. When a protein is purified in which the redox status is 
important, such as PDI, small thiols are frequently used to reduce the protein after which 
they are separated by column chromatography or other techniques. Au-DSP-GSSG can be 
used to rapidly detect contaminating LMWT in the protein sample after the separation 
process to ensure its success. A third application of this reagent could be for an 
environment in which small volatile thiols like H2S are routinely used. By employing the 
reagent as a sensor in the workspace, hazardous levels in the air would be detected in the 
event of leaks or other containment mishaps. 
With the hypothesis that the size of the crosslinker controls the size of the thiols 
able to reduce the disulfide bond, the next step in the project was to systematically vary 
the crosslinking agent until the probe became cleavable by PDI. Four peptides were 
purchased to this end: GGGC, GGGGC, GGGGGC and GGGGGGC. It was thought that 
after oxidizing the peptides they could react with DSP via the terminal amines similarly to 
GSSG. However, a complete and functional reagent was not formed with any of these 
peptides. The smaller two appeared to be able to form the reagent (see Figure 3.9); 
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however, the fact that it was not reduced after treatment with 200 times the amount of 
DTT that was effective on Au-DSP-GSSG means that it may not have been formed as 
initially believed. The presence of high amounts of salt will cause AuNP to flocculate 
regardless of other molecules in the solution. The salt concentration in the G4C-CG4 
solution may have been high due to salt mixed with the peptide in the vial it came in, as 
well as from the phosphate buffer salt after the newly oxidized solution was concentrated 
by lyophilization and resuspension. Therefore, the solution may have turned blue when 
the peptides were added because of flocculation induced by salt, and not by the reaction 
between DSP and the peptides as with GSSG. 
Another reason the reagent may not have reduced could be due to the final shape 
of the crosslinker. Glycine is a hydrophobic amino acid, and hydrophobic groups tend to 
aggregate together as protection from the environment. If the reagent did form through 
the reaction between the oxidized peptide and DSP, then the glycines may have clustered 
such that the disulfide bond became inaccessible to incoming thiols. 
Regardless of the reason, these peptides are not effective as crosslinkers in a 
reagent for detecting thiols and alternatives must be explored. Future continuation of this 
work is to find a molecule that is as successful and inexpensive as GSSG, while being 
large enough to accommodate PDI and other HMWT. This may be insulin, which is a 
physiological substrate of PDI (110), or another peptide designed to be large with an 
accessible disulfide bond. 
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CHAPTER 4 
THE THIOL PROTEOME, AND RAPID DENITROSYLATION OF S-
NITROSOTHIOLS USING A FLOW DEVICE 
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4.1 Introduction 
As described in Chapter 1, thiols are responsible for the redox state of proteins 
and thus their activity. In addition, RSNO5 - including both low and high molecular 
weight molecules - are important reservoirs of NO. S-nitrosothiols transport NO through 
the bloodstream and release it where appropriate, allowing NO to perform its functions 
when denitrosated. Thiols can only do this when in their reduced, sulfhydryl state. 
Therefore, the redox state is important for both proteins and NO to function properly. The 
characterization of thiol-bearing proteins - referred to here as the thiol proteome - is 
useful because thiol proteins have such an important impact on signaling, enzyme 
regulation, and other aspects of physiology (111-112). Additionally, the subset of the 
thiol proteome involved in NO transport is important to study, given NO's tremendous 
impact on health and disease. 
This project had two overall goals. The first one was to characterize the thiol 
proteome, and identify specific proteins bearing surface thiols. This was prompted by 
experiments in which AuNP were mixed with samples of plasma or platelet-rich plasma 
(PRP), washed, and subjected to gel electrophoresis. Each time the same proteins seemed 
to be present in the samples. Under the hypothesis that proteins rich in surface thiols 
would be the ones to bind to the AuNP, a systematic protein identification process was 
begun. Mass spectrometry and Western blotting were performed and a total of 7 proteins 
5 Abbreviations used in this chapter: AuNP, gold nanoparticles; DTT, dithiothreitol; GSNO, S-
nitrosoglutathione; HMWT, high molecular weight thiols; LMWT, low molecular weight thiols; MALDI-
TOF, matrix-assisted laser desorption ionization - time of flight; NaSH, sodium hydrosulfide; NO, nitric 
oxide; NOA, nitric oxide analyzer; PDI, protein disulfide isomerise; PDMS, polydimethyl siloxane; PDMS-
AuNP, PDMS-bound gold nanoparticles; PNGase F, peptide N-glycosidase F; PRP, platelet-rich plasma; 
RSNO, S-nitrosothiol; SDS-PAGE, sodium dodecyl sulphate polyacrylamide gel electrophoresis; TEM, 
transmission electron microscope. 
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have been identified so far from plasma and platelet surfaces, hypothesized to be 
members of the thiol proteome, including PDI which has 2 sets of surface vicinal thiols. 
The S-nitrosoproteome is a subset of the thiol proteome. It is the set of proteins 
that are nitrosylated in a given tissue and condition. The second goal was to use AuNP to 
rapidly identify 5-nitrosoproteins using a flow device of our design. Using GSNO as a 
model RSNO, it was first shown that AuNP is able to 5-denitrosylate the GSNO either 
while free in solution or when bound to PDMS. Next, a flow device was designed to 
enable higher throughput of this reaction. The first model was built, and at the present 
time the process is manual. However, the ultimate intention is to optimize the flow device 
for plasma samples so that it can automatically quantify the total plasma RSNO content 
and identify the 5-nitrosoproteome. We furthermore aspire to identify the specific sites of 
S-nitrosylation. 
4.2 Materials and Equipment 
4.2.1 Materials 
Argon Grade 5 300 SZ: Praxair Distribution, Division of Praxair Canada Inc., 
Mississauga, ON 
Dithiothreitol: MP Biomedicals, Solon, OH 
Glutathione, reduced (GSH): Sigma-Aldrich Canada, Oakville, ON 
Gold (III) chloride (HAuCU): Sigma-Aldrich Canada, Oakville, ON 
Mouse anti-HSP70 antibody: Abeam Inc., Cambridge, MA 
Mouse anti-PDI antibody RL90: Abeam Inc., Cambridge, MA 
PNGase F: Sigma-Aldrich Canada, Oakville, ON 
Rabbit anti-mouse antibody-HRP: Abeam Inc., Cambridge, MA 
Sodium hydrosulfide (NaSH): Sigma-Aldrich Canada, Oakville, ON 
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Sodium nitrite (NaN02): Sigma-Aldrich Canada, Oakville, ON 
Sodium phosphate dibasic: ACP Chemicals, Montreal, PQ 
Sodium phosphate monobasic: ACP Chemicals, Montreal, PQ 
Sylgard 184 silicone elastomer kit (PDMS monomer and curing agent): Dow Corning, 
Toronto, ON 
Trisodium citrate: Sigma-Aldrich Canada, Oakville, ON 
Trypsin, sequencing grade: Promega, distributed by Fisher Scientific Ltd., Nepean, ON 
4.2.2 Equipment 
2 ml glass vials with black polypropylene screw top and septa: Supelco, Bellafonta, PA 
27.5G syringe needles: Becton-Dickenson, Franklin Lakes, NJ 
Bio-Rad PowerPac basic power supply: Bio-Rad Laboratories (Canada) Ltd, Mississauga, 
ON 
GyroMini nutating mixer: Labnet International Inc., Woodbridge, NJ 
Hamilton® syringe, 1800 series gastight, model 1801RN: Sigma-Aldrich Canada, 
Oakville, ON 
Hettich EBA12 desktop centrifuge: Fisher Scientific, Mississauga, ON 
Immobilon™ PVDF transfer membranes: Millipore, Etobicoke, ON 
MALDI-TOF DE-Pro mass spectrometer: Applied Biosystems, Foster City, CA 
Micro-C18 ZipTips: Millipore, Etobicoke, ON 
Philips CM-10 Transmission electron microscope (TEM): Electron Microscope Sciences, 
Hatfield, PA 
Polystyrene 24-well plate: Sarstedt, Montreal, PQ 
Polystyrene 96-well plate: Sarstedt, Montreal, PQ 
Sievers 280i Nitric Oxide Analyzer: General Electric Canada, Mississauga, ON 
Type 37900 culture incubator: Preiser Scientific, Louisville, KY 
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Vacutainer® ACD Solution A blood collection tubes and PrecisionGlide Vacutainer® 
brand blood collection needles: BD Canada, Mississauga, ON 
4.3 Methods 
4.3.1 Synthesis of gold nanoparticles 
Gold nanoparticles were synthesized as described in Chapter 3.3.1. 
4.3.2 Synthesis of PDMS-bound gold nanoparticles 
The synthesis of PDMS-bound gold nanoparticles (PDMS-AuNP) was adapted 
from Zhang et al (83). PDMS monomer and curing agent were mixed in a ratio, r\, of 0.04 
and incubated in a culture incubator at 70°C for 1.5 hours for the curing process. A 
mixture of 10 mM HAuCl4 and 5 mM trisodium citrate was incubated on top of the 
PDMS overnight and washed four times with distilled water immediately before use. 
4.3.3 Isolation of plasma from whole blood 
Whole blood was collected from healthy donors into 8.5 ml ACD collection tubes 
and the cells were allowed to settle overnight. The platelet-rich plasma (PRP) was 
removed after settling and either used or centrifuged at 900 g for 15 minutes to remove 
the platelets and use the plasma. 
4.3.4 Isolation of proteins from serum 
4.3.4.1 Using aqueous AuNP 
500 [xl of AuNP were saturated with 10 mM NaSH for 10 minutes after which the 
excess was washed off by centrifugation at 14000 rpm for 15 minutes. This and a 
separate, untreated 500-ul AuNP sample were each mixed with 1000 [il of plasma and 
incubated on the nutating mixer for 15 minutes. After the incubation with plasma, the 
samples were again centrifuged at 14000 rpm for 15 minutes and the supernatants 
containing unbound proteins were aspirated. The pellets were washed 4 times with 10 
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mM phosphate buffer, pH 7.4, by resuspension and centrifugation. Upon completion of 
the last centrifugation, the pellets were resuspended in 20 \i\ of buffer each, mixed with 5 
[il of 5X loading dye, and subjected to sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and mass spectrometry analysis. 
4.3.4.2 Using PDMS-AuNP 
All samples used were prepared in triplicate in a 24-well plate. The setup of the 
experiment is shown in Scheme 2. The 12 wells on the left-hand side of the plate 
contained PDMS-AuNP; the 12 on the right-hand side contained only PDMS. Half of the 
wells of the 24-well plate were pre-treated with 10 mM NaSH for 10 minutes, indicated in 
Scheme 2 with "+" or "-", which was afterwards washed off with 4 rinses with phosphate 
buffer. Then every well of the plate was incubated on the shaker with 400 u.1 of plasma 
for 15 minutes, and again washed off with 4 phosphate buffer washes. Finally, 400 \il of 
10 mM DTT was incubated for 5 minutes consecutively in each well of a triplicate series, 
thus pooling the protein elutions without increasing the final volume. This was done for 
half of the triplicates; the other half had the same procedure done with the phosphate 
buffer, as shown in Scheme 2 with "+" or "-" referring to the use or absence of DTT, 
respectively. 
Following this procedure, the proteins were then concentrated by acetone 
precipitation. Each of the 8 samples were mixed with 3 volumes of ice-cold acetone and 
incubated at -20°C overnight. The samples were centrifuged the next day at 14000 rpm 
for 5 minutes. The supernatants, i.e. acetone and buffer, were pipetted out until -100 (xl 
remained. Then the samples were spun in the speed-vac until the volume decreased to -20 
\il, which took about 15 minutes. They were each mixed with 5 fxl of 5X loading dye and 
subjected to SDS-PAGE followed by mass spectrometry analysis. 
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PDMS-AuNP PDMS 
Scheme 2 Experimental design for the isolation of serum proteins using PDMS-
AuNP 
All 24 wells of the plate were filled with 300 \i\ of PDMS monomer and curing agent. 
AuNP were formed in the 12 wells on the left hand side by mixing AuCU" and trisodium 
citrate to final concentrations of 10 mM and 5 mM, respectively, and incubated overnight. 
The second and fourth horizontal rows were incubated with 10 mM NaSH, which was 
washed off after 10 minutes. Then equal volumes of plasma were added to all 24 wells. 
After incubation and 4 washes, 10 mM DTT (first and second rows) or buffer (third and 
fourth rows) was added to the wells and the protein samples were collected in the 
indicated triplicates. These 8 samples were then concentrated by acetone precipitation and 
subjected to SDS-PAGE and mass spectrometry analysis. 
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4.3.5 Identification of the isolated proteins 
4.3.5.1 SDS-PAGE and staining 
Typical 10% SDS-PAGE protocol was used for all the samples from the above 
two sections (113). Afterwards, the gels were stained for 1 hour in Coomassie stain and 
destained overnight in 40% methanol and 10% acetic acid. 
4.3.5.2 Analysis of gels 
The Coomassie-stained gels were scanned and analyzed by the computer program 
Image J. Each lane containing the proteins that had been bound to AuNP was selected and 
a histogram was prepared by the program. The histograms plotted the locations and 
densities of each protein band, allowing comparison between samples +/- NaSH pre-
treatment as well as comparison between aqueous and PDMS-bound AuNP. 
4.3.5.3 Mass Spectrometry 
The 10 strongest bands from each gel were chosen and prepared for mass 
spectrometry analysis as described (114). Bands were excised from the gel, destained 
with acetonitrile and ammonium bicarbonate, and dried in the speed-vac. They were 
deglycosylated by incubation with PNGase F overnight, followed by washing and trypsin 
digestion for 8 hours. The peptides were extracted using a mixture of formic acid and 
acetonitrile, then concentrated in the speed-vac. Desalting was performed using micro-
CIS ZipTips and then the samples were spotted onto a MALDI plate in a 1:1 ratio with 
matrix (a-cyano-4-hydroxycinnamate in 50% acetonitrile and 1% formic acid). 
Matrix-assisted laser desorption ionization - time of flight (MALDI-TOF) 
spectrometry was used for protein identification. For each sample, the protein fingerprint 
from the tryptic peptides was acquired in linear mode. Two of the strongest peaks from 
the fingerprint were chosen for further analysis, which was done using post-source decay 
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(PSD) in reflector mode. Peaks from the 11 subsets of each tandem mass spectrometry 
were stitched together in the program Data Explorer. The fingerprint peaks were inputted 
into the Protein Prospector database to identify candidate proteins, which were verified by 
the peptide sequences from the PSD. NCBI Structure searches were performed for each 
identified protein. The crystal structures and full protein sequences were obtained and 
then viewed in the program Cn3D. 
4.3.5.4 Western blot 
Western blotting was done on samples of platelet-rich plasma (PRP) and platelet-
free plasma to probe for PDI and heat shock protein 70 (HSP70). Samples were run on 
two gels in SDS-PAGE and transferred to PVDF membranes for 1 hour at 110 V. The 
membranes were blocked overnight in 5% skim milk in tris-buffered saline (TBS) and 
washed in TBS 3 times for 5 minutes each. Mouse anti-PDI antibody (RL90) was diluted 
1/1000 in TBS with 2% skim milk and incubated with one membrane on the shaker for 2 
hours. A 1/5000 dilution of mouse anti-HSP70 antibody was incubated with the other 
membrane. Following the incubations and four 5-minute washes in TBS, rabbit anti-
mouse secondary antibody, conjugated to horseradish peroxidase (HRP), was diluted 
1/2000 and incubated on both of the membranes for 1 hour on the shaker. This was again 
washed in TBS. Finally, the membranes were exposed to luminol and the 
chemiluminescent reaction performed by HRP was imaged. Immediately afterward, each 
membrane was scanned to acquire an image of the protein ladder. Once identified, PDI 
and HSP70 were also searched in the NCBI Structure database and modified in Cn3D. 
4.3.6 Synthesis of GSNO 
S-nitrosoglutathione was prepared as previously described (115). Reduced 
glutathione (GSH) was prepared in distilled water and mixed in a 1:1 (mokmol) ratio with 
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chilled sodium nitrite in 0.5 M HC1. The mixture was incubated at 4°C for 30 minutes and 
then the GSNO was crystallized with cold acetone. The powder was stored at -80°C. 
When needed, the appropriate mass of GSNO was weighed and dissolved in 10 mM 
phosphate buffer, pH 7.4. 
4.3.7 S-denitrosylation of GSNO by AuNP 
4.3.7.1 Aqueous AuNP 
2-ml screw-top glass vials, as used in Chapter 2, were filled with 200 \il of either 
AuNP, or phosphate buffer of pH 7.4; 8 vials of each type. These were all degassed in 
argon for 7 minutes each. 500-ul GSNO solutions were prepared in vials in the following 
concentrations: 0, 1, 5, 10, 50, 100, 200, or 500 uM. All of these vials were degassed as 
well. Then 50 fxl of each GSNO solution was injected using a gastight syringe into its 
corresponding vial of AuNP or buffer and these samples were incubated for 10 minutes at 
room temperature. Following the incubation, 50 \i\ of air above each solution was injected 
into the NOA which contained 10 mM phosphate buffer, pH 7.4; the NO in the air was 
detected by the machine and displayed as peaks. As in Chapter 2, peak areas were 
compared to nitrite standard curves, which were generated afterwards, to obtain the 
concentration of NO detected. 
4.3.7.2 PDMS-AuNP and PDMS 
The same experimental design was performed as above with the following 
exceptions. The concentrations of GSNO used were 0, 1, 10, 50, 100, 200, 350, or 500 
uM. 200 \il of these degassed solutions were added to degassed vials containing PDMS-
AuNP or PDMS using a syringe. After the 10-minute incubation, 1 ml of air above the 
solution was injected into the NOA. Data processing followed the same procedure as for 
AuNP or buffer. 
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4.3.8 Flow device design 
A flow device was designed in the SketchUp program for Mac OSX. In the model, 
two tubes act as inlets and then merge into a mixing chamber inside the square device 
foundation. Two outlet tubes also emerged from the mixing chamber: one to release the 
merged liquids, and one to connect to a nitric oxide detector. After the design was 
prepared, a prototype flow device was assembled. A teflon square was made 
approximately 2.5 cm x 2.5 cm. A similarly-sized glass microscope coverslip was sealed 
to the bottom using PDMS, and teflon tubing was used for the inlet and outlet tubes. 
PDMS was used to fill the teflon square and a hole in the middle served as the mixing 
chamber. 
4.3.9 S-denitrosylation of GSNO using the flow device 
Serial dilutions of GSNO were added to 12 wells of a 96-well plate, 100 [xl per 
well. The concentrations used were 0, 1.34, 2.68, 5.37, 10.7, 21.4, 42.9, 85.9, 172, 343, 
687, and 1375 \iM. 100 \il of AuNP were also added to the 12 adjacent wells. One inlet 
tube was placed in the GSNO solution of the lowest concentration while the other was 
placed in the first well of AuNP solution. A pump was used to induce flow through the 
tubing into the mixing chamber and through the outlet. The mixture was collected from 
the outbound tube using a syringe and injected directly into the NOA. This was repeated 
immediately for all dilutions of GSNO and their corresponding wells of AuNP. 
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4.4 Results 
4.4.1 Synthesis of PDMS-AuNP 
Gold nanoparticles were successfully synthesized on the surface of PDMS using 
Adam Faccenda's (Mutus lab) modified protocol which involves 5 mM trisodium citrate 
and a higher concentration of AuCLf than the originally published method (83). The result 
is a deep red to purple colour, indicating that this PDMS-AuNP has a high density of gold 
nanoparticles formed; this was verified by TEM. The higher density of nanoparticles 
provides an increased surface area onto which thiols and proteins can bind. 
4.4.2 Identification of AuNP-bound plasma proteins 
Part I of the project was to examine and identify components of the thiol 
proteome. Both aqueous AuNP and PDMS-AuNP were used to this end. First, one 500-[xl 
sample of AuNP was saturated with NaSH, and one was left coated with citrate; 1 ml of 
plasma was added to each 500-^1 AuNP sample, which was then washed four times and 
run on a gel. Figure 4.1A depicts the gels that included the supernatants from the washes 
to verify their effectiveness at removing unbound protein. The gel on the left contains the 
sample that did not have NaSH bound before mixture with plasma, and the gel on the 
right contains the sample that had been saturated with NaSH. The supernatants from the 
first centrifugation were diluted 1/100 and 20 u.1 of each were added to lanes 2 or 8. 20 fxl 
from each subsequent wash step were added to lanes 3-6 and 9-12. The AuNP samples 
containing their bound proteins were loaded in lanes 7 and 13. B is an image of the gel 
whose proteins were excised for mass spectrometry; it shows the AuNP-bound proteins 
after the final wash. 
A separate experiment was done to isolate plasma proteins using PDMS-AuNP. 
Wells of PDMS-AuNP were either saturated with NaSH, with the excess washed off, or 
81 
untreated. Plasma was incubated on the surface followed by washing. Then the proteins 
that had bound to the surface were eluted with excess DTT. Control groups were eluted 
with buffer rather than DTT, and all groups were repeated with PDMS alone, making 8 
triplicates in total to fill the 24-well plate. Figure 4.1C depicts a typical gel after this 
process. While the PDMS-AuNP samples that were eluted with DTT had many bands, 
there is evidence of some non-specific binding since certain proteins appear in samples 
from PDMS in the absence of AuNP. The strongest bands were prepared for mass 
spectrometry analysis. 
The gels from Figure 4.1 A and C were compared to one another using the 
program ImageJ before mass spectrometry was performed. The program analyzed the 
lanes containing the proteins that had been isolated by aqueous AuNP, and the lane 
containing proteins eluted by DTT after binding to PDMS-AuNP. The order and intensity 
of the bands were plotted on histograms shown in Figure 4.2. The AuNP were saturated 
with NaSH to ensure that proteins would bind by thiol exchange rather than by amines or 
other functional groups. It can be seen from the gels and the histograms that the proteins 
were all found at the same molecular weights whether they bound directly to the AuNP or 
exchanged with NaSH. Therefore, saturating the AuNP with NaSH was not necessary. 
Another observation is that there were several proteins that may be common to the thiol 
proteomes of aqueous and PDMS-bound AuNP. The most notable examples are the 
proteins found at -65 kDa, -50 kDa, and -23 kDa. The main difference between the two 
types of protein isolation is that these three proteins are much stronger in the PDMS-
AuNP samples, making it more difficult to identify other common proteins. However, 
since these same proteins bind to PDMS alone as well, their concentrations in the samples 
may be at least partially due to non-specific binding. 
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Figure 4.1 AuNP-bound proteins 
500-^1 samples of AuNP were incubated with plasma, either with or without pre-
treatment with NaSH. The samples were washed four times each and 20 [xl of each 
supernatant were loaded into gels, along with the final samples of protein bound to the 
AuNP. Additionally, samples of proteins bound to PDMS-AuNP with or without NaSH 
pre-treatment were eluted with DTT and run in a gel along with control samples. The gels 
in A show that 4 washes were sufficient to remove unbound proteins. The samples 
derived from untreated AuNP were run in the gel shown on the left, and the samples from 
NaSH-saturated AuNP were in the gel shown on the right. B depicts the gel whose protein 
bands were excised and prepared for mass spectrometry. The gel in C is from the PDMS-
AuNP experiment. Lane assignments are as follows. In A: Lane 1, protein standards; 
lanes 2 and 8, first centrifugation diluted 1/100; lanes 3 and 9, supernatant from the first 
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wash; lanes 4 and 10, supernatant from the second wash; lanes 5 and 11, supernatant from 
the third wash; lanes 6 and 12, supernatant from the fourth wash; and lanes 7 and 13, 
proteins isolated by AuNP. In B: Lane 1, protein standards; lane 2, proteins isolated from 
plasma by AuNP; lane 3, isolated proteins diluted Vz. In C: Lane 1, protein standards; lane 
2, proteins bound to PDMS-AuNP with DTT elution; lane 3, PDMS with DTT elution; 
lane 4, proteins bound to NaSH-saturated PDMS-AuNP and eluted by DTT; lane 5, 
NaSH-saturated PDMS and DTT elution; lane 6, PDMS-AuNP with buffer elution; lane 
7, PDMS with buffer elution; lane 8, NaSH-saturated PDMS-AuNP and buffer elution; 
lane 9, NaSH-saturated PDMS and buffer elution. The masses of the protein standards are 
shown in kDa to the left of the gels. The banding patterns of isolated proteins are similar 
whether or not they were exchanged with NaSH, and when the AuNP were aqueous or 
PDMS-bound. However, the concentrations of certain proteins vary in different samples. 
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Figure 4.2 Histograms of the protein banding of pre-mass spectrometry gels 
ImageJ was used to plot histograms of the proteins in lanes 7 and 13 of Figure 4.1 A above 
and lanes 2 and 4 of Figure 4.1C. Despite differences in the relative abundances of each 
protein, the four histograms reveal similar patterns of proteins in the presence or absence 
of NaSH saturation, and when the AuNP were aqueous or PDMS-bound. This supports 
the hypothesis that AuNP will bind to the same proteins based on the proportions and 
localizations of their cysteine residues. 
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After qualitative comparison of the protein contents of the gels, MALDI-TOF 
mass spectrometry was used to identify some of those proteins. Linear mode was used to 
acquire the fingerprint of each protein, and PSD mode allowed the identification of the 
proteins via their sequence. The mass spectrometry raw data can be found in Appendix A. 
Proteins identified by this method were histidine-rich glycoprotein precursor (60 kDa); 
actin (40 kDa); filamin A alpha actin-binding protein 280 (280 kDa); myosin heavy 
polypeptide 9, non-muscle (226 kDa); and tyrosine-3-monooxygenase/tryptophan-5-
monooxygenase activation protein, zeta polypeptide (28 kDa). 
In addition, Western blotting was performed to probe for PDI and HSP70 as they 
were suspected to have bound to the AuNP. Two gels were run containing protein 
standards, washed AuNP-bound PRP proteins, washed AuNP-bound plasma proteins, and 
in one gel, purified PDI as a positive control. After the gels finished running the proteins 
were transferred to PVDF membranes and Western blotted: one using antibodies against 
PDI and one using antibodies against HSP70. Figure 4.3 shows one representative blot for 
each protein, with A as the PDI blot and B as the HSP70 blot. Since both PDI and HSP70 
had bands in PRP and plasma, it can be concluded that they were both pulled down by the 
AuNP and thus may be part of the thiol proteome along with those identified by mass 
spectrometry. 
86 
A 1 2 3 4 B 1 2 3 
1 250 
fcTl30 













Figure 4.3 Identification of PDI and HSP70 by Western blot 
Gels were run containing samples of PRP and plasma and Western blotting was 
performed to probe for PDI and HSP70. A shows a blot for PDI. Lane 1, plasma; lane 2, 
PRP; lane 3, PDI control; and lane 4, protein standards. B shows the blot for HSP70. Lane 
1, plasma; lane 2, PRP; and lane 3, protein standards. The molecular weights of the 
protein standards are shown in kDa to the rights of the blots. Bands were observed in both 
the PRP and plasma for both proteins, making these two putative members of the thiol 
proteome. Other proteins were identified by mass spectrometry. 
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4.4.3 Properties of identified proteins 
Since the identified proteins most likely bound to the AuNP through their thiols, 
their cysteine content and structures were searched. PDI, HSP70 ATPase domain, actin, 
certain domains of filamin A, and myosin heavy chain were found using NCBI Structure 
and viewed in Cn3D. A glycoprotein similar to histidine-rich glycoprotein precursor was 
also found. The cysteines of each protein were highlighted in red; it was found that there 
are several thiols or disulfide bonds at the exterior of each protein. Figure 4.4 shows a 
compilation of these proteins with the surface cysteines highlighted in red. These are the 
main candidates for the binding sites of these proteins to the AuNP. All of the proteins 
were also determined to be present in plasma and/or platelets, supporting the accuracy of 
the present mass spectrometry identification. Table 4.1 summarizes the location and main 
role of each identified protein. 
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Actin Filamin A Actin-binding protein 
- domains 23 and 18-19 
Glycoprotein HSP70 ATPase 
domain 
Myosin Heavy PDI 
Chain 9 
Figure 4.4 Structures of identified possible thiol proteome members 
Seven proteins were identified as putative components of the thiol proteome by mass 
spectrometry and Western blot. The structures of seven of these were found in NCBI 
Structure searches and viewed with the program Cn3D. Cysteine residues were 
highlighted with red to indicate their locations in the proteins. It can be seen that each 
protein contains cysteine residues on their surface: these are the possible binding sites to 
the AuNP. 
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Table 4.1 Locations and functions of the identified proteins 
Protein 
Actin(116) 
Filamin A - actin-binding 














Plasma and platelets 




ER, cell surface and 
platelet surface 
Serotonin-producing 





Promotes orthogonal branching of actin 
filaments; links actin filaments to 
membrane glycoproteins 
Role in blood coagulation and 
fibrinolysis 
Protein folding 
Role in cytokinesis, cell shape, secretion, 
capping 
Protein folding; platelet aggregation 
Binds phosphoserines to mediate signal 
transduction; cytoskeletal structure; 
possible inflammation regulator 
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4.4.4 AuNP can S-denitrosylate GSNO 
Part II of the project entailed the characterization of AuNP-mediated S-
denitrosylation of thiols, leading to the production of a flow device for high-throughput 
analysis. In the first experiment, 50 ul of degassed GSNO were injected into vials 
containing 200 |i,l of degassed aqueous AuNP or 10 mM phosphate buffer, pH 7.4, in the 
following amounts: 0, 0.05, 0.25, 0.5, 2.5, 5, 10, or 25 nmol. One GSNO sample was 
injected per vial, totaling 16 vials. These were incubated for 10 minutes after which 50 [xl 
of the air above each solution were injected into the NOA in duplicate. The peak areas 
were translated into pmol of NO detected with the use of a nitrite standard curve. The 
amounts of GSNO mixed with AuNP plotted against the amounts of NO detected by the 
NOA is shown in Figure 4.5; no peaks were detected when GSNO was added to buffer. 
As more GSNO was added to the vials of AuNP, more NO was released until the AuNP 
surface was saturated at about 10 nmol GSNO. Data presented are the average of 2 repeat 
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Figure 4.5 5-denitrosylation of GSNO by AuNP 
0, 0.05, 0.25, 0.5, 2.5, 5, 10, or 25 nmol of GSNO were added to vials of AuNP or buffer 
and incubated for 10 minutes. Then 50 ul of air above the solution was injected in 
duplicate into the NOA. The resultant peaks were compared to a nitrite standard curve to 
calculate the concentration of NO for each sample, and these concentrations were plotted 
against the amounts of GSNO originally added to the vials. The graph shows that 
saturation occurred at 10 nmol GSNO for 200 [xl of AuNP; no peaks were detected for 
GSNO added to buffer alone. Each data point is the average for 2 injections, with the 
standard deviations denoted by the error bars. 
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4.4.5 PDMS-AuNP can S-denitrosylate GSNO 
A similar experiment as described above was performed in vials containing 
PDMS-AuNP or PDMS instead of aqueous AuNP or buffer. The amounts of GSNO used 
were 0, 0.2, 2, 10, 20, 40, 70, or 100 nmol; and 200 \il were added to each sample vial 
rather than 50 u.1. In addition, 1 ml of air was injected into the NOA instead of 50 \i\. 
Figure 4.6 shows a plot of the amount of GSNO added to PDMS or PDMS-AuNP versus 
the amount of NO detected by the NOA. As with aqueous AuNP, the NO release 
increases with GSNO concentration until the surface is saturated at about 40 nmol GSNO 
for the PDMS-AuNP. In contrast, in the absence of AuNP, PDMS alone caused little S-
denitrosylation and there is no apparent saturation point for the GSNO concentrations 
used. Data points are the average of 4 independent experiments, and error bars represent 
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Figure 4.6 S-denitrosylation of GSNO by PDMS and PDMS-AuNP 
Various concentrations of GSNO were added to vials of PDMS or PDMS-AuNP. After a 
10-minute incubation, 1 ml of the air above each solution was injected into the NOA. The 
PDMS-AuNP surface was saturated by GSNO at about 40 nmol, while PDMS alone 
bound less GSH, releasing less NO, and did not saturate. Data are the averages with 
standard deviations of amounts of NO released, detected by the NOA (n=4 for each 
point). 
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4.4.6 5-denitrosylation of GSNO using the flow device 
The original flow device was designed electronically with the aid of SketchUp for 
Mac OSX, and then assembled from teflon materials and PDMS. Figure 4.7A shows a 
sketch of the design, containing the inlet tubes, mixing chamber, liquid outlet and the 
outlet to connect to an NO detector. Figure 4.7B is a photograph taken of the prototype 
model and apparatus. 100-|al samples of 12 amounts of GSNO in buffer - 0 0.134, 0.268, 
0.537, 1.07, 2.14, 4.29, 8.59, 17.2, 34.3, 68.7 and 137.5 nmol - were pumped sequentially 
from a 96-well plate through an inlet tube alongside 100 \i\ of AuNP. They were injected 
into the NOA after mixing with AuNP inside the flow device. The resultant graph is 
shown in Figure 4.8. In this experiment the AuNP saturation appeared to occur at -10 
nmol. Since there was no significant change in peak area beyond that point the two 
highest GSNO concentrations were omitted from the graph. Data points are the average 
peak areas of three independent experiments, and error bars represent the standard 
deviation of each average. 
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Figure 4.7 The flow device 
A flow device was designed on SketchUp for Mac OSX and a prototype was built. A is 
the computational model with two tubes as inlets, one for RSNO and one for AuNP; an 
outlet for RS-AuNP; and an outlet for NO to be hooked up to an NO detector. The centre 
of the flow device contains the mixing chamber where the RSNO would bind to the 
AuNP. B shows the implementation of the design. A 96-well plate was filled with 12 
GSNO samples of varying concentrations and AuNP in adjacent wells. This was 
connected through a pump to the teflon flow chamber. An outlet tube on the right can 
connect to an NO electrode and a tube on the left released the GS-AuNP mixture, which 
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Figure 4.8 S-denitrosylation of GSNO using a flow device 
100 ul of GSNO in buffer was added to 12 wells of a 96-well plate in the final amounts of 
0, 0.134, 0.268, 0.537, 1.07, 2.14, 4.29, 8.59, 17.18, 34.3, 68.75 and 137.5 nmol. The 
contents of the first well were pumped alongside 100 pil of AuNP where they merged in 
the mixing chamber of the flow device, and the combination was injected into the NOA. 
The other dilutions of GSNO were pumped sequentially in the same manner. The peak 
area, and thus the amount of NO detected, increased with the concentration of GSNO. 
Beyond 10 nmol there was little change in area, indicating saturation of the AuNP by 
GSH at that point; consequently, the two highest concentrations of GSNO were omitted 
from the graph. The data shown are the averages of three independent experiments and 
the error bars represent the standard deviations of each average. 
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4.5 Discussion 
Chapter 3 described a novel AuNP-based reagent for the detection of LMWT. 
Here, the use of AuNP was extended further as an agent to detect thiols in plasma. The 
aim of Part I was to use AuNP to isolate these thiol proteins from the rest of the plasma, 
enabling their later identification. Part II used AuNP as an integral component of a flow 
system in which GSNO was 5-denitrosylated by thiol binding to the AuNP. The ultimate 
goal is to extend its use to proteins to identify the S-nitrosoproteome and the sites of S-
nitrosylation therein. 
In Part I, aqueous AuNP was initially used to pull down proteins from the plasma 
and later PDMS-AuNP was used as well. Since thiols form near-covalent bonds with 
AuNP, the hypothesis was that these proteins were isolated on the basis of surface thiols, 
as those would have the best access to the AuNP. After several gels were run the similar 
banding patterns made it evident that the same proteins were being isolated each time. To 
ensure that the common factor between them was surface thiols, additional samples were 
prepared in which the AuNP had been saturated with NaSH. Thiols can exchange at the 
surface of the nanoparticles but cannot be displaced by other functional groups whose 
interactions with AuNP are much weaker. Figures 4.1 and 4.2 show that there was little 
difference between the proteins isolated by untreated or NaSH-saturated AuNP, giving 
credence to the hypothesis. Additionally, it can be seen that gels in which PDMS-AuNP 
isolated the proteins exhibited similar banding to aqueous AuNP-isolated proteins. It is 
important to note that the relative abundances of each protein differed between the two 
methods. This point will be elaborated upon later in the Discussion. 
Once it was established that certain proteins were repeatedly isolated from plasma 
using AuNP, mass spectrometry was used to attempt to identify them. The first samples 
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were isolated using aqueous AuNP and prepared without a deglycosylation step. When 
they were analyzed on the mass spectrometer there was difficulty in mass fingerprint 
acquisition and PSD analysis. Of the 12 proteins analyzed, only the histidine-rich 
glycoprotein precursor and actin were identified. Since proteins destined for secretion are 
glycosylated in the Golgi of the cell (122), we thereafter incorporated a deglycosylation 
step in sample preparation. A deglycosylating enzyme, peptide N-glycosidase F (PNGase 
F), was used on 10 protein samples before trypsin digestion. Filamin A actin-binding 
protein 280, myosin heavy polypeptide 9 non-muscle, and tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase activation protein were identified 
following the modified protocol. Additionally, actin was identified for the second time. 
While the deglycosylation ameliorated the identification of these proteins, it also 
brought a new barrier. The mass fingerprints for several samples contained many of the 
same peaks; these monopolized the detector so that most of the sample-unique peaks were 
not strong enough for PSD analysis. The protein sequence of PNGase F was searched in 
the NCBI Protein database and the "peptide cutter" tool of ExPASy was used to 
determine theoretical tryptic peptides. It was found that the masses of these peptides 
corresponded to many of the recurrent peaks of the mass spectrometry samples. 
Therefore, it was determined that PNGase F contamination precluded identification of 
more proteins than those listed above. The third mass spectrometry attempt used proteins 
isolated by PDMS-AuNP rather than aqueous AuNP. Although the washing protocol was 
followed stringently after the deglycosylation step, PNGase F-specific peaks were present 
in all 10 of the samples. The peaks unique to each sample were insufficient to identify the 
proteins. 
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These results obtained are purely preliminary due to the difficulties in the 
identification process. Protocol optimization must be achieved prior to subsequent work 
on this project. One potential method of avoiding PNGase F contamination could be to 
deglycosylate all of the proteins before running the gel. That way the enzyme would have 
its own band in the gel at -36 kDa and not be present in the excised protein samples. 
Alternatively, chemical rather than enzymatic deglycosylation methods could be 
explored. 
Seven proteins were nevertheless identified by mass spectrometry and by Western 
blotting. The protein structures were viewed in Cn3D whenever possible. The cysteine 
residues were highlighted in red and the proteins were shown in Figure 4.4. All of the 
proteins except for HSP70 had more than one cysteine at the surface, and in several cases, 
such as PDI, the cysteines were vicinal. These residues are the most likely candidates for 
binding to AuNP. The cysteines of HSP70 ATPase domain are partially buried; however, 
the flexibility of proteins may allow one or more cysteine to become exposed and bind to 
the AuNP. Additionally, HSP70 may have instead bound to AuNP by its substrate-
binding domain or C-terminal domain. Therefore, these structures strengthen the 
hypothesis that surface thiols cause the selective binding of certain proteins to AuNP. 
Table 4.1 is a compilation of the localizations and functions of each identified 
protein. While 3 of the proteins can be found in the plasma, the others are located inside 
the platelets. This suggests that some platelets remained in the plasma after 
centrifugation. Subsequent plasma isolation procedures should therefore use higher 
speeds and longer centrifugation times to ensure that all the platelets have been removed. 
Once proteins are identified, the next objective will be to verify the binding sites 
of the proteins. This may be accomplished as follows. The proteins would be isolated 
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from the plasma by incubation with aqueous or PDMS-bound AuNP. PNGase F would 
deglycosylate the proteins and be washed off. Then the samples would be digested with 
trypsin, followed by washing. At that point the only peptides remaining in the sample 
would be those that bound directly to the AuNP. They could be eluted using an excess of 
DTT or another small thiol, separated with high-performance liquid chromatography and 
spotted onto the MALDI plate. Once the masses of the peptides and PSD fragments were 
detected, database searching would reveal the sequence and the specific cysteines that 
bound to the AuNP. In summary, there is more to be done to identify the thiol proteome 
in addition to the steps that have been made. 
Part II was the progress toward building a flow device to identify the S-
nitrosoproteome. AuNP had already been shown to be capable of S-denitrosylation by 
binding to the thiols, thereby releasing NO (123). Here, we used this knowledge to test 
our experimental design before using it to determine whether or not PDMS-AuNP S-
denitrosylates thiols as well. All of the samples of GSNO and AuNP were kept in screw-
top vials with septa and blown with argon before use. This was because GSNO may have 
partially S-denitrosylated in the buffer, either spontaneously or after exposure to light. 
Argon treatment eliminated the NO from the solutions and the air inside the vials. 
Therefore, any NO detected by the NOA was purely from the S-denitrosylation by the 
AuNP. Additionally, only the headspaces above the solutions were injected to eliminate 
the possibility that GSNO would spontaneously S-denitrosylate inside the NOA through 
the bubbling solution or through reaction with ozone. 
As seen in Figure 4.5, no peaks were observed in the control containing only 
buffer without GSNO, indicating that the purging with argon removed all NO from the air 
in the vial. It was also demonstrated that all NO detected was the result of S-
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denitrosylation by AuNP, since no peaks were observed when the GSNO solutions were 
added to buffer instead. The clear saturation curve indicated that the limit of the surface 
area of 200 ul of AuNP was 10 nmol of GSNO. 
The next step was to test the ability of PDMS-AuNP to S-denitrosylate GSNO. 
PDMS-AuNP would be useful in a flow device because it is immobilized, allowing a 
sample to pass over it without dilution. The experimental design used was similar to that 
of aqueous AuNP. 200 \i\ of PDMS-AuNP or PDMS control were prepared in vials and 
degassed; degassed GSNO samples were injected into those vials; and the NO released 
was injected into the NOA from the headspace. Here, an additional concentration of 350 
u.M was used and more nmol of GSNO were added to the PDMS-AuNP or PDMS vials. 
The result with PDMS-AuNP was a similar saturation curve as with aqueous AuNP, 
shown in Figure 4.6. In this case, the saturation limit was about 40 nmol from 4 
independent trials. These data show that PDMS-AuNP has potential as an S-
denitrosylation agent in a flow device. 
One problem observed in this experiment was that PDMS alone 5-denitrosylated 
GSNO in the absence of AuNP. Furthermore, in the thiol proteome portion of the project, 
the controls showed that nonspecific protein binding occurred as well. In both sub-
projects, therefore, the use of PDMS has had drawbacks. A solution would be to find 
another substance that can immobilize the AuNP while remaining inert to the proteins and 
other molecules added. One possibility is organometallic chemical vapor deposition 
(OMCVD), which synthesizes nanoparticles on a glass surface (124). Thus alternatives to 
PDMS, or improvements to the methods currently used with PDMS and PDMS-AuNP, 
should be explored before a flow device is planned that incorporates immobilized AuNP. 
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With that in mind, we designed a flow device that utilizes aqueous AuNP. In the 
trial model the solution was pumped into a flow chamber along with a sample containing 
GSNO. When they mixed, the resultant solution was injected into the NOA. Figure 4.8 
shows that as increasing concentrations of GSNO were pumped, the amount of NO 
detected followed the same saturation curve as seen in the prior Figures. As this was 
simply a more streamlined approach to the same experiment that yielded Figure 4.5 
above, the similar results were expected. However, half as much AuNP was present in the 
solution with the flow device, meaning half the surface area was available to S-
denitrosylate the GSNO compared to the original experiment, yet they had the same 
saturation point of 10 nmol GSNO. This is likely to be because the GSNO solutions were 
not degassed prior to mixing with AuNP, and the solutions themselves were injected into 
the NOA rather than the gas headspace. This means there probably was NO in the 
solution other than that released by AuNP and this would have been detected, skewing the 
results. Therefore, the design of the flow system may require modification. 
Ultimately, the desired system would be fully automated so that the researcher 
would only need to apply the sample, such as plasma, to acquire the results. Total RSNO 
of the sample would be quantified. Additionally, the flow device would be used in 
conjunction with high-performance liquid chromatography (HPLC) and mass 
spectrometry to identify the S-nitrosoproteome. Finally, the sites of 5-nitrosylation would 
be identified by the method of thiol binding detection described above. The use of an NO 
electrode would ameliorate detection since the NO released from a protein or small 
molecule could immediately travel to the detector, eliminating the need to inject the 
samples manually. Thus, Parts I and II both have future work to be accomplished but the 
groundwork has been established with promise for important results to come. 
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5.1 Conclusions 
Nitric oxide and thiols are intimately linked in physiology. As molecules that both 
protect and transport NO, thiols have great influence on NO signaling. Conversely, when 
NO is bound to a protein or small molecule it may act as an inhibitor, hindering reductase 
or catalytic activity. Both are found in high concentrations in the bloodstream, making 
blood an important tissue for NO and thiol chemistry. For these reasons it is difficult to 
study one without considering the other. 
The first project studied the role of nitric oxide synthase under hypoxia. In 
experiments using cells, inhibitors and purified enzymes, it was concluded that eNOS is 
the one NOS isozyme capable of reducing N02" to NO when limited oxygen supply 
precludes its proper biosynthesis. Since oxygen is dependent on blood flow, endothelial 
cells are among the first cells to detect the decrease in supply and it is logical that they 
would be equipped to compensate for it. NO produced from extracellular nitrite can cause 
dilation of blood vessels to transport oxygen and generally restore conditions to normal 
when possible. Even in hypoxic conditions, NO would depend on the thiols in the blood 
to operate after its synthesis from nitrite. 
Next the gold nanoparticle-based reagent was synthesized. By virtue of their 
optical properties and a disulfide bond in the middle of the crosslinking GSSG, the AuNP 
were used here to detect low molecular weight thiols. It was found that only molecules 
less than 310 Da were able to cleave the disulfide bond; the rate of this reaction depended 
on both the size and the concentration of the thiol. This gives it potential to quantify the 
total LMWT in plasma or other samples, which could be extended to a comparison of 
plasma small thiols between conditions. For example, since RSNO cannot reduce 
disulfide bonds, their concentrations could be calculated indirectly by the loss of free 
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thiols from a pool measured before and after an NO donor is added. Therefore, this rapid 
reagent to detect thiols has usefulness for studying both thiol and NO chemistry. 
The third project applied gold nanoparticles to both protein thiols and RSNO. The 
AuNP isolated certain proteins from plasma repeatedly. Seven were identified by mass 
spectrometry and Western blot. Based on the structures of the identified proteins, and by a 
comparison of the gels when NaSH was exchanged or not present, the proteins were 
likely bound to the AuNP by their surface thiols. This began the work toward 
characterizing the thiol proteome of plasma which may be extended in the future to other 
groups of proteins. 
Both aqueous and PDMS-bound AuNP were also used to begin the process of S-
nitrosoproteome identification. AuNP were shown to S-denitrosylate GSNO to establish 
that AuNP could be the basis for one or more type of future flow device that would 
rapidly and automatically quantify RSNO in a sample. It will be modified to identify the 
S-denitrosylated proteins, thereby revealing the S-nitrosoproteome. Finally, the sites of S-
nitrosylation of identified proteins will be identified as well. The prototype model is 
manual and requires optimization of its operation. However, it is able to S-denitrosylate 
GSNO and shows the potential of the flow system. 
The importance of both small and protein thiols has been stressed throughout 
these three projects, as well as the connection between NO and thiols. The correct 
oxidation state of thiols must be maintained to keep individuals healthy, and gold 
nanoparticles have been exploited in several applications that may aid in identification of 
this state. Therefore, the present advancements in NO and thiol research have interest in 
medical, academic, and industrial settings. 
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APPENDIX A 
Below is the mass spectrometry raw data used to identify the proteins actin, 
filamin A actin-binding protein 280, complement ClqB, histidine-rich glycoprotein 
precursor, myosin heavy polypeptide 9 non-muscle, and tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase activation protein. The fingerprints for 
each protein are shown, as well as their PSD data that aided in the identification. The 
fingerprint peaks that were used for PSD are indicated with stars. In addition, the last 
figure shows two examples of fingerprints in which PNGase F tryptic peptides are 
suspected to have contaminated the samples, precluding identification. The fingerprint 
masses suspected or known to correspond to PNGase F fingerprint masses are boxed. 
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